var title_f34_43_35504="Asymptomatic microhematuria";
var content_f34_43_35504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Algorithm for isolated asymptomatic microscopic hematuria in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 605px; background-image: url(data:image/gif;base64,R0lGODlhywFdAsQAAP///4CAgH9/fz8/P7+/vwAAAEBAQMDAwO/v79/f3y8vL8/Pz5+fn09PT19fX6+vrx8fH29vb4+Pj9DQ0KCgoPDw8HBwcDAwMA8PD1BQUODg4GBgYCAgIJCQkLCwsBAQECH5BAAAAAAALAAAAADLAV0CAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIVDFAGJiouMjY6PkJGSk5SVlo0UhpqbNgYOAqChoqOkpaanqKmqq6ytog4GnLKzLQYEtDAEsbi8vba9LbrAw7K/xCnCx8qDxsslyc7RfM3SANDV2HXU0tfZ3nDbCwQECCwRCzQDZAvlyLvf8G7bDBAOCSwDtyYFLPxFBOpugBJxTkW3eAjPbAOQT4SAAQ3QEWjQQF/DCAMGPLBWQAADAA8gogPAYIADfyMm/5ost6DBAAEAJNwjuSABg4cMWja4R+CBgwHoBEAQQO6hgHI2cerk6dJBuYwCbN5rOUDCs3cJs5ZZ2FBCAwALHiSAkGDsvYYbEZBNUIBA2AYIxiJ4AJdtiZoxHQDAwM5qBJgIMCAgAIHcUAQS9D5EsAADSQUEEnwCIEAvYcNHE4O9p9mBA3L5xva9qrU0Ga63GCjIGRMmZasNCWDEcMtfg09CJ24EgFIE4gYK1EGIQA7AWJKWA8ZWN5DhuICORTgGKGI5gN/BKbvOJyECioOmw2tBLUL20OYD8z1QgK6hv6rjQOvrDUCBhMHqfgsG0EC1ROW3UNdcPtTxNgI/BVpnH/9+2lVHQHMmgCfehFWQxw5IQClQXXsPeocAZLyVI8BX1yXw13X0FVBOSdaIACJhASUYIHOATachfxtNZA2AO4ZIEnPeOUeYCCOlhBWFSFKxTQQYsLfeAOxRpoAC25ETHHC3CKCAdxEEp0ACCEBFHz0mqQPcliNAsJuMPQoF5W4Z5ZQRUD061yOZPxkX3AINaQkRaUkGOsVCVxzHAoRLSCjookgQaoUDHx3qGhOKMmrpEI4qU+mlnPqQ6TGbdipqDp9GiIQ+KDAQ6RGoujPqq0CUWkJARtB6AqI24IqCrd8dCeuvNyzEAF1wPWQVZSKE1MBGUUUl2QCRhqSRQyahU5L/PcbdBK1DyUK0m0MR/KSPsugkBe1S1jT11EtSZZvtg8g+G1GEvgJrrwxcRYAYZGrdw896cX1UALuFIdDfAhAEDEC4YD3AAFxDEsYOBOj8q4DCIzyUAMIg1ZXwZWplphdenX0W5ozWYNAATPxsDBYE9N4rMw3kscnPsiT4w2d5O2EggT77iVDRhgUOdPO3JDR3M26FsUkddjQ62GOBBiI3AH3W1Dvz1inUzCM/DR1YXozqJOBn1VILGZDRdpqgNEM/j8OgndQtKGCVU9PKT7j+xsz13yt4LTU/lRGJ9n4CyHQPAmBHukB318FcYJSE6wVW0q4RTmJcTquj4o+UBYkz/4tUg72RXYACrroJgtvJDwIOBMfyCOsp4FQCXn7EZ0YPwD5ljhhAmfl1sb+EuQj+dAllAp2TBEGZegIFY56lvzxABFiHurrMshpBdRnab29v9//wOkb44v9KPi/op//q+ri0776o8NMi//yc1r9EWV7cj7+lnnCFAAd4CqgQ8IAIrIzW/gcsRFzigRCEhAEMEMEKWlARmWCgBqOQiA16kBYHOMAGNhDCD5rQEBwogAoL8IETulAQG1hhATLwwhr6gQIy7IANd6iHCshwAjwM4h0uoEIOCPGIdLCACjeAxCbCwQMqzKATp7gGFVaAilhMgwEukMUumiEAFvCiGMUwAf8PjPGMaEyjGtfIxja68Y1wpMEBLkjHOtoxEgeI46UC8JIE+vGPgCzFAAKgR0sFYFKDEAAhC7moQxpCkYxsJCIFAclIBsqRhaikJZGESUJocpMT6mQiFwlKFszxjqhMpSLySARRUpKUpVQBHwNJy1qCYpBFcGUgPhlLFOiyDbwEwi/BMo6ZAIF/RGrHwkaAFxIESQURWFUMgtnLEgxzDdT0wTBN8pBn3iBsGZtU2B7wzOCNIAIh8QgySDSDbFZTBNdUgzt5sM1bMI5ILtmNAEISJNgZ70fGG8tkwjmCsGELOWQpaEdUMICZDIsiizOKMkswz2rGMw0V1UE9X6YnMLn/ZyMNsAqITlSc/nzoZ8eT2odGsKwIHAudL5EmCcJUUH11BiaFuxUs32nNSbohoznYZnAoFpM+Gs8fAEEYKPJktgEMpW0ElZqqfOOYBdyIIAYRJ8qisxcUALWUF0XDV29Qz8AE5TPFrBpACACZcdRETQ0Cp0O0Wp92MCB4VzPmCuAlNeqgBGsO2akOTqnKwhrWEqy8wy/FERkbIBMGF9rBWG2w0cYMJmGGS959+EIktopgMtMiQYECExfL4Yggx2KBZAqKMpzpSKc/mKUtZ0tbVuASD7/k5mpWoCsRTDUGBZGsYGPr07SpBgGqeRNvoOQUsHgJJsVbGUiykzQvMWs3/4Fh5lVZcLG+qmN3dIKtNov7yjzk1p78yMnPECBRhrCLMiuxRmqIdQ8G3MMm74KJfRfGuxKw9yXl6Im4xDuEsKYAsDjYbg1uUoPJvsDAfHAwGs5rHMc4lSiTKZxnyHGikMTVpnqxDgFUBhO0RE6vGVZMQznmtuGOtwYItsFcdLDbdrqYrOTd5Y3hkNtPQOAjYeOqY5qDgVAQrsQoEzGtYjObVgm5QWhL2o53AGE8SLgFVdbDlb9YXPi0I2x/hXJb4hPXJKOMauqJklzD/LYW5zLHfdjyCrKcBzmTgcKsFVqOviKAIFXFcOlp7UZIt+QOXQdELN2zmAksBDrjoFXmKP+SV7clXOLG4LGRXSaR9KrpIDCmB3YeA57TBt5y7clgU+Izkqf2POoV+kMQQTSR5hSU4bk5BRqgwAZaSFk4/8B8DIV0CR52HR6MtQAG6AAQ5+xrt9EVJOWklbbI2YMCLcCbOQi1GBwdhmBWwAMWSOEKcewCcsVkJBIISnzHMVVlMYt48TU3CV5CkXY8pLlQYR5F9NEsMP2k2YF9gQw/sAEKaMCXAE9p2w7KAAck1CEDM8FDd0Kt5v43msb5ybyEQhSbsDdjCPBnwqVs3pGTQZNzJKIMV0hHAwCcLnFJmGVHtDCYeFgAGIgmwPB7M6s84C0xn6jxvFJzDAFgwwgrS0L/BxaVkQJcABSsxMpXyAELmJEEdIZQQ1aqZ5f69iHUnjeIi+7hE7HIZRxTTWSoQ1SOOX2aU3YDt8GAcguofOotB/htQFGYx3S3yKA4sp5zdvRl3WPvuZn3fPZi5AZJwDWJq5pSKwNst0WdElNXYbKXPYKs0/W32bWqM09gHcALgB/7KVDDr1Yn6nQmJ+fJEwy0HYa5f8HbHtiAuFVIbnzErTiMy1x8soQ3sSGHNvCRm+KRx5vhNwg9s7NGW93SgmOv8AIWSKwJPJ/n7pIErwXgtAmsM+ZxqFUdfDNQgZ6WsI9NX9LVj3sbbK+DT4vgsUe5P/yxnYJ55joDvFYDBkZz/yVSH+uxEX92OehhORXTIjVHgHGxfHQBN4AGE6LHEA14HZx1OYcifyLAARvgAVfEbDEwWoKxWoO3MKm1K0l2LOgAIh42LXbhWXXyE3phVoYzex64BvQnA7hCNc3BdfwRNNPGf7dWYAmnPF/iAN6BMOxwJqrmG8UzO34yAOWghHoFJRmBDqimAFEoJVTCfETyXPFnadNkXZSBXVx1gSlgHV34FVZFEd/1PNhTHdBibeE3hsIDdyV3KGbjb/80cfa2buriXlGRErTSHL8lUKtyepVHUTvYa48UiQ9mciigYDxgV6Z1BLQHBmHFdLhzCydyPTHxFR32XZyhFxumTEDoGv/e1x0TSBJgZ4SQ+GaTaIY1MGNAQCZWqASd+AWfSCSxpw5gxniBdx1ekR0/mIgwgYL1gQ5B02m8RYk00INv8ItYZ4lWRo1nEIzSFx8cwnzldwt2EzWixYwLsxtskREYIFNl2EraSAfY2HnxaAfzyAXeiIOXgxZfkYAVsyJA4l+YVR+3QCuQ0zE+yI0yYI0mgHE5cG0k8FsykACPB3+MRmX1WAf3uAXe6Fx7qIV08obOAz24E17JQoayMQJRIh0T9Y5IyFtP5xof0pI08D291QI613cqsJEMqVrixwUbqQX0J1c64AAW2WAKGQMXlW/w1VzSgoDvxWBJ41srcg/yZm7/TyMACwAKCxApFEkC6SYCYels04iLQnCTWhCUWTCUwoYD7pgrSQkDF7WKp4gwCrOKLjIr5NCOBgJzcuGXH6MOtqMdpBU6JDBz7DQrb0ly2tRHtRUKBvSYtHVbipWRXqCW2QiT0mFkCeAz/IZIvAIKNxERZsI0E2GaAOEZc3V0H/FwI6Aa3jdsj5gxcZkChHVYijBBuLmb2lcHPZkFmEmPmtl8ZGY2ygiaz1Bv0FJivxcmzUkABfBjq4kwsThTCyVxsdl/tdkEITRCJWQvv4kFwQlPvtZn1eGC/HNP5llQJjCYEgAiEGg2m8M8ViidA6KTJKAABzhs2amdZLB7LHQv/+Hpk0kwngBwUSX5hKlWkruVoNawiULzEaizMF5yD1hIHY1xE66hGibAhC8jaQUQHKS4k9vJBDG0QjQEno4pmZC5oix6SyXKAgNaHT/JA5ACBAb6Azi0QjpkL7e5m7l5eUC6CL0pTJaJAh4qBIbyAznqAz60QpzXRR30BjMqVjG6BCpnRF7UnSRUpBN2pNd4pUqgRAXARF4EoAHIg2D6U2KaBFBUAFKURSeqQinKBlV6Bk36A1YkRjuqQj1qp2sKTG2aBFs0Rk+qQlGqBndqBnmqTWE0RllKpYHKBo3aA2V0RmRqpvPnoi/aqX9EmTzlBG8ap2vwo0MqQUJ6qpLgpf+hqgR7mhBT2qrMwEVZEauyGghglBBc+p1tYKqq+quJwKqicqkIgaZUyqmemqygeqtaMKczJKlzUKnMOgN9WgB/CqjROqjT6qQ/BK1yIK3bGgOR6q1xAK5k4KvAmq7BmkRLxGOTKp7aGgeylaz0KkjxSgWj6q4owFjUdxfeIZHwCgyLegXmigSvKnfkxU3q9AzmCJz3Sq4a+bCDQqsQu3yvaRI8ETXPIqGRciyThF8kUV/E0pL7NKLqNQ4+QZS0KbDvCpQSKwW5qq+kFzfIBTGSEzUF0x99iQH0ybBSQ4pElzMgBRtD8SArBjMXOQsDawUFewTEWrEFhRsJMDQYeDf/O5MuzvEJEvB4/CU9PFKMhNcjYdNmR4gLS1sFTVsNG5U2BEIj68ccEmCFtwFpbAK2xkcdY2trZUsLZ0sFaSsNaxsTHnKzDYI4VmFVVgEcJiB6H1KQt1CdYuh1eSuGe6u0LbsFfxsNges7+tkmNjclzbUX9QVswIElDCGi8DcwtvMUn0m5tdgLfTsFmesMsYsPbRllCcmyKIBciVOjOzCb30EDQYmu6lq8lSCsC3m56XC7MeaSZkteVEIAEoC0QdC8YcsQwhuv81qv3EtAyyqJ3/qy2BohtNIOVykS/vVvYOGVftFf6sdvBNFf0KlOG4qx2WIsXqW9yitPV1q7TDC7/13wS4FBHObrMXNhwPkpilERHZqRFku3aCBxYmxBfells9ZQMK7JmC+2Cb/ov0sAwPhIXk2FAXqBeIVhwqgyeXmiswklGwNAGwbSZi4Mw2FGtV6bNq+7wZrQwfsru+KrpixQGMkHGs2ZEu+3IzuzHuEoeH2pZrUhNmHTtjiswT3gwXTXv8javY/5vbKwWPrQL/EZnyOgjyPxPB9hno1rIJBjF2gMIp+jxoNbJypLGfrLCb9IvMZ7WMhrCL80tc/TuRS6PIH8JYdJhjGBtLBmuq9Dh69zJfCJJq8TO53LJpWrUT6FKo8lBPbnA5vMh7dqxU4QlLqEEmjpAnPsr0AAkf8+W5af3MMEW8clQMqugZUpGxYm4VtQYRz1gFPlESAEoCr4pRKhmzH8JIWB+Dhu4RLNqDvKTBlF60/DHHCtvI1Gug+QaXMGrDEZyh8fUVIMcFJP/Hw5xwAYmoqxPLQEWXQXNmKjQR18gRiPERkhBRLwB8IbBMpNIMo+VX6TgcJtNhBN9VRgOxDN8TTJyCtIBRTD2DbDURxsR8A1aHiVbFHFRRWPdiodWM2xTFBDzF62BgpjwSyrVjUE7Rp1cx/fc35sBY5tox8M4tJU03AwTMWh+ksUQ5MyALw9oNP6vA8EFcYfTRQ3Alq7sR8ZZtKeA5AbrYJk3Db60Fbq8NTjcCP/+nAiNM1TujS/39xe7CZNgoi/yIIhONNvG9stoXVv1mK/5hIps+wtE40DoxxVWPjP0HUln6sO0wsROIXUIyl7B8JcLEGGYXMm3kEdhG2HNyGiJPvDTaRLE7wAKUYZ4yx2+2IYfbNzAkMw5HAwCYNfDBMWD3NZFzwxDYjZb917XGC9TMrYSPRL/vBkumIdrnNaxne1E9GZKLUXymTD4rA2s4Mz+avRqe2LrH1Erk25TLx8NgNV5zc2xnE2vRHFz7GaYHO7dCzctzjNPn1aOhLbKDPbOZWBuv0a6dk4RAI5alEnlEMZDHja4LvDxS1Exw0WtAZlyv01xCM7aFM7t5M7//TNO5wLPHtoIL7zT1dtyXYc30GEz4+m0+4tgK58ab77wQrOQwx+AyntvPSUxd0bmVo8ClxM0dT8A3isrrqZx46wx6B04cTtmxUericwTMFlBJ1sA6r84GewqyoO4/DIgjpwyodJizKQ4dIcB8bK406wTV5BcWItEbUcEpZTEgG1y2Ftfl0dzIUYkblMEvR1HQ/hEsEtB85ap0i+BNs0doD5XxvDlzrrzeBM0jg1zuWcF89QDjp7PYihF2ZXefbcA9V6rWWeBBtl2KZJ1899YW3jDyXt3FBTAgG9au4cYHz+4kZwqAWQqIF+BINOjM1J1yFdZmK46D1SjiTw6YHWI/8JHeZyMK6ZrgSbThnzSdc0SNQseXR77dyfwyJG/FmQLpiPO+nsWqatbuYJ+91zHdRHZ9fThdfPI10FrQ54wivR1evOdRvAPgf5OuyCHuFoS+lHcLDabgQsXqDebgSFGu5IMO5I0OeOiu7pzu1+W+5F8LQzU+Ionko7Xo3wfgLWnQI1nrvubk0c/uG2FOJB5cqn7OCoDJcB31PZGgR0JmB0YhPwMhFDI1AWmE/cYi5WAbL7deXdnOUvwO5UpO5nea9ZZ4WNkTIrYxZmAc6441FPDDJkwSY4F01zrhk62PCZGb4Qb4kDMt2t4RCwcQtxe0uzIyM2z9eNvvM8T54Pj93/1VclRQN5q1YZ8dE3Ss8jz14fKK3wK0vi9z72q2q5UW+WU6+BdXKBdDIthNEODSgjjAuffJ3rYF/kVTzwBL/3DyHvQrnv+YzyQP/HOZKIUzLL2ZFcnYsgPFK6dO/c0e7JOpxJfr+WgP+/gj9Nlw9qsJzdnGDyQaCW3HdynU/5Zm8Cg5H1LHDjLvDvh0JpLiD6m/8EPQ3fp/8M50EULEDk5EskQp4qX4HT/in1Z1/Fs3+ZlY8Fv/Q9D6APPSEv/xGy7gL9ztxxH/Ff+SfxkJZvFs9vf4jj+j7ik+9JyX8Fy5/7v0wi/YF2hGsd7B/PPRvZ2ky9n/UZSWcWy3WIOTz+/8UPAoA4kqV5BsK5sq37wrFcCsF847l+pyehEIIJACaRgIgYjkEBQBgABgQnFKBkUkVP4ggDEKgATRIYIAkLJGJWbffqueNyXHtugtvz+l197//L4JFskaWpRDgMNW1JZSEqZmWNrZWtFX6hqUya9PkJAoLmdOp9tgQRIMQY5VSNLKSGnozG0v6VRo4cQQwNPAAkLEI1+DJA9f4uKmgJ+xI0YIpsQi8oRy1YytoA3tZ2c2p7hsEUgEH4vjAw5EhHXJc0gs56z7vdEmAM5KsDNDiILEAYECGYk4BLAAAUOEbflgX5BlyrJK2SAAUKwkgjAy4cvY40NpIS92LMgyolG/9ckzDEyoIgABAsUZFgn5ovJQqU9GdliIABKI84kLlkH4MFEh6IEwArhjyPTmFwe+qn6ZwAA8Bgzap1K9euXr+CDQt2AMg8pRhggOBuxBgJ/h40QHAEZs0iZYAAiKAJwIMihNiqa6BOioRnCx4gUCBhCgRUgqNAEPBjyo8bVKViLhE1s53LcQ4ECC16NOnSpk+jTq169eoD20SKwFCgwDMSBQYoGJCqXzkCAK34AwMQzEEpQSWcuSmijBQGCoqKaORQyzN4SgA42CfDM2fMm7vH4Q5+fMdSEGbrZFsw1YDFQdg7mwJmcpCIEnT3m2J7uYpGBCJEFgVlVTCiHxELeGH/WVkxgMaagw9CSJprOnxHnigLWpghPaUs0M9S0Yhw3xe1yWXFAEhgggAG7lxDjRoNVLMfNFK8wpcx52CQShoCjiBAgApSeJVYQxJZJFZk7VBhhga+IJ6GT9oCWwuTOOBPBLkpsBIG+5RBDW5hFGGiCWMwR8ADWF5zJhRnKuAAfLkU8CFTGL4hpYZOomCnH/C4MUkrTdIJZQseTCgoD3oaKsN1dATagpKc4XkHol/4tMAC+ySgBgNwxdVTTQKUFMEvEAT1y1BJcIqApyJEkE8z5KgTxknnZJPoDBY0aqtmk+rawi4XUsgreJHuykJhCCGW4xeiCoSABEAg8CtO/EiQ/9hiADSGwGPNPovKr75Ea0QBvq1xplzafdMrDBcYoC5UwrrbWa4rPJoZsSRE5Rx02Knzq39VNDJGgQgRWN2A0VHWKgZTTNLEMIDGy4IGs1UQMQv1WqzDvSJgLNXGHE/6X4AAwYVwJAEvwyMhAxMixZnXoAwin2zMqysFs3mQcZ4ynCKnzjQHywICBi4gKi3t1Br0CjWWFF1jJrfMMKtqHEOEjlQfLKAAoibGMCxNCKDTWun+PMIGs1lQNr7wRlMOrW78ZWEnBRjQwQR1GjtuyrTM3ONGdNv9LgtqKuCOcyP8a/JtbaaiJl8WuakywKjkBqN8CojaBEy5IfqxhhzMdv+B2iPUS5JJlf7CQE/7dHhMAkug9EVkTMJ0FUI1GWWi7Vakuqocc89WwAcbUKABvYhGptMPqy+XkwivD0CUUQTMtHqHDQxRzO59L/d38MMXfzHbImQ3zrA1JzpB8AUYP/pZaY1tiVt8xTUXAWpFu0ACWSIgRQItIsE51CMBXvTCD6WsyAm7GUwEnAWtX8VhAAYYzfrWxwEL5GxtS1OAirSwi/yJITD9csxgZnc/byllfqjgx2CYhLgJiqaCwbtgBjWoChSN5Hyj68D6KDA6AJRCNrS5CW50w4+g+CgIVQDDfcBguysQhATDCRsUEvOc5/UkQInjUQRhGBoZzqZud7P/oQki8KJmLHEvmJiOEwy2t8QlIIv9cWF0vBgAMAJujGT8oUZGl4H1beCH5kGPcu7HHvegghBYccApEvCINcTNCUCoD6uUdQRflOlkdGSUbYJ3AQsUSlIrgEBuSBWJMpBJMgQyhn6iRoVLzmiTwAsdKB01voh5zkIV5IAgpdShyMlIRAIgUQIIUThD/sN1ySiBilj0uDNJknxz1OTvNsKBDXigYi64BTVE0EFjXiOVVvsC1t44oMpgZ5pkE8E1sym4HSAgfqGIJycFiT5dlW4EVcoLloqJj4skAUsPSMhAohM9KWJJAAAZwj4dULlpujI899zjCMw4gmHc40sgggab/yIHD1duwaE+UedHknRLExTNGykFkj35CMSTmuJPOvtYx57iOSVtqgGdak/qljMAB+iPAQRQgTMaoJ+SHKN2DVTVVVJRvYPOxKdAhVhL+VhTFkQyYzSFqVNuCi9uPbCYUEAEsu7RAAEcwQi7AMi5AHDFgZYqbAV5hVq2QNbDUNV9E03UVV2aNBz0tSNehcEWpbAFZe0tOeRMAAau1c0uQFaRqhznnKy6V0MF1q99zEFm5zHYFxRWidg4ZSZ+UREp/KlhpN1CRlqQywyFxqUd09Y1kFZRebYgHZmJALr8pjRDfdYFoWUE6wjxWIisAgFxCpNcHuaMSBzTGKzLq9pia//Vk+6IiybbDlf3kBifbdVWwW3BcKHgEFf9pSIA3R9u1KGmAfzvIdfIKEAb8pC3reC1FrJuL2eQGMQNMy4q06l+oIepJeyuR6FKwvQoFbnWqaB2bnKJTVhyrZ4AU3Xr5IGQjOThD28FSb+1UFbrqVfZ3hIpADaDwdKaVmyR0K1TKJVtfNEAqs3OgE1bkbOoxZcFSMRpktFxK2Lk2xw0KEJKXvJpQnmoJ5WYpSe+7gwkgzj9NIEwaJAAG53x2EqoJwvwwABWmgCBCKzQAcPgCUa2S2Yw+GnDmo1DZ4F7WSjx1323tPJ2szzUTKwMtfxRjpixfIopOKsBylLCwoLMxXH/nQJxcp6zSSn9hTs/Kc/VvaVuTVYyGlUDIuNMg4pSYUAZWRQePEWIE0QwSValQVTA2O6q1yLTS1taDhhbqTdWwQdMa0jTZcNYAlpRRFE3Qr2yglwqnKNT2CzOo/rRlkWeASPMfSE3uomWQrZLbQXUhgDpOXKuK82zW+sgyiXotMaADVt3w/akjARFa/m2ks2We8QveILvaoeGUNVuCtCLnY8kQ2E0xLGYU9AeduFNHmH/rGNHwO0c6h0KBxitpPnWtwtOGC4Z50UTgcHeb/6HkAACIY5tFsNVVK5AFlbZ4eOBuM7qrFn9WhpjUZviQcRpCSiSdqOTKEMcT7RnmYOH/+YZs7lfcU5pnU+OPuTyeRMeGUVHDx2t5oDGdpDeHaVbjOkudfqcoY6wZv7DEkFWZjTNIOsxZB2dNK5sVfu78ZjfnbO3dKWXAEr1k3c7CtHjdkGxUQaRnhXvdddz3rve+CdTmuxf9/rXu5tryftV7HeifGbAHjHN/xDzKLa06L3D+c53GMSqXz3riSTix8cA9HI7vVQ8H68kMzn3pzGAHXXve9E4Gfa2JD3tn2J74dvh+Mh/uOXFW3ynKH/59Xi+9DkSeeqXB/vCP8ABNrAB7lefr81PVOlrr33Yg+574cfs+O1s2fX74WzBywD88Zz61uM//1l5fXXP//ibBU8H1P/fk+De7xngAZZG8NWc/zVeBayPHg1gBEqgozBg413AbPDSBGrgBuJLBeadBcxGIHHgCE5g9JFgCXjAbPjQCeYdobAgvXhg3lHMC94drtDgHcTg3RmA6NxgvrFLD3YgEMZe2gghpU1MAWgTEJrgDU5ADRWhXwGgE97gEj5hFf6Q/BGhEuagFXLhU6QfD2phF4phrqlP8LRPD1LhGKqhrfBQ8KwgGm4hASLgHI6GAq5hLPxR8IggHA6gVejfHzpRHHbhLglhGuZc+8WDIIqhIcIfI5YdIgJC+d3hNilixFUi8z2JJE7ixVzi0nVi0kHiH2jiJqLAJ36eKXKG7OXBKJL/omagors4omZ9h6V4E8XpALrhWyvSQixWHy+OHnmFibqtgwuwoi5yzCuqiy9SGXnJFSEUQyIsR8Ll1E7VRKtUjcV1jzHWgjIiHzcyHnk9gVhZQVzcTzS0HFh5yxCAi7QQIzLyYRF646YJVxAwkjDoh6j5Sdb4h8JIjWu54xT+o63E47DxSiNEDyspzpVp0svwCDbimjbGwkA2nkTWXEFSRkC43UugSD5q0ta8BF44ZDEaI0XeHUmGnUUa1Es4lAKcA0dGTWL4BEi2I0RGZEDylU2WRyhOBU6eoEnmm0/GiyrKC02GAlDmmlEmo07ugUjqIlI+HU/Og1DOAVO2olOW/x1UeoNUVhNRgoJVyiJWdoPY+dpQcqUtgOW79eH9rV4+/CH/laVZnOV+xWUsFKDv8R4d2uFbTt8TeuVEzmVT/mXSBaagcJ/3gZ9eBttgpqJiPkn6zcYHIGZi8iVjaoj8zQb9RaZcTuYdAuBsCGBmPhxlmt8dOmDwQCBoLuZm3uEFFkAGoqZgquYagmAB7OFrpiY8imaGpGABvKFtdl5uQh9w6hIS+ubkxeYa7mBxGidubmIAZKFyjiZzTmITQudvHmd1YieFCGf2ZWd3aud1emd4UiJ4WowG0OF5oqfvnWE31GV6PkheRuV2bohoHkBkAOJ94ieIQQB82oJa5qdYuP9lcJJnxBwALkbgAPCn9UFKJfalbNGngQ4ggm6IUroBVXLigN4ehNafhEYlhf7abRbig54gh2alh7YbiIah2hToiCboHmillEVniI7OippApvBZFMhAjejAWM4Bu0VQi4bECbTEAL0Aj7aaicVoipYNjZKAczyAM+iENHAPq9giOvRWeJDULQLpDOTRzpjAT1XElZqAbqkasFindC7prYWJCKhFCAnEqJQKwyUBTzjPIOhHGBQFIvGOTq0EhslJ66hBGLgEGACFCggqZRCAbp2EPJFoHqwP+JzhLTSCcpnKQdnIMQgBqRiqGawEdCzqXyXpO6ZpCaATrInBFNyYtVD/xgI1pAhdgiUY3Z9FQQPND5GRwMT1mDiBgaqqnaFiAG/BhVxAgJxAwAacJx7RkKQKnBdki2CwVVTtqmJIjQPURQIE61xMmkc06PupqEzFDSqlDDwUnRb1I5hx3ULcKURBwZsJwCZIQMb1aixtVBlUAm8kUQkU67GCkRhJalBAQFEUDGNdi7yuwW9ch70+jcaZHoa6C5M+Dw7BnMAgJCxlks8NGqymq+ScaqT1iEjoqjp9bHQgkpw0qh2szyeFkqQuRioEmmnlBsGiq1FFwchmK3ei6c84rMj+g7KMQao1QzWUSsyY67siw3ZlEiPgziCgyDUoS1z1B46kgtMuBzG9/8OWykA7JSFFbVdsXE1ygc3TblQxoMgwedO9kVuoAuSM3lrt5IM7RFvjvCziTZPFamTgwcPRVtG11UaPVI4ZBETilYHjSMDfGqo4XAlumG0UWG1V2MnMdJRcYEmsqIDjTMKWVFQ/1ex8Mqy65KwGluwumqiZLuzN6kznTuDnRmToIqnxyWd8qi2LTqgOnamMdivsdqjsji7tjioJom5Rqi6Msu7m9orpSmDvduXvKl7uKinO2ud/Ou/zcsV+boh/Qm9XBKi2tm5WiqZ5umfu3WX35t561kJ7Ktn3/t7ibkP2hqX6zm4Vbmv6Ci/pyq8nxm8PFub3oe8A3u9hWmL93v+gYwrPEwIwZA4b++6iATuFZRYAZgqhAjPwAvovDXZmAXymEE5wBUPw/Fphac7Gad4gBxeAB59iBNMga7pmEZrwlOmuGs5mbQphC6vw8o7hbvamENJwDIvqGs6gFe5wAZMwDSYnFwZx//3wCzpnFx4xDqftdEphEVKnEtPg+4rnHUoxEU+xN5Av+GrxFtfheGrwFfdn9YrxGO9fo1SxD4PxNiLv9XnxCodfFnNxa5SoEHrGGfdv/fkhGRfJ9b4GHZsxAhclIAfCGp9oWBLyzf1xER9iJvrfixJfG8twLx7y6vquH0NyDoefI3+oIVsyBSry000y8FYyENaxIMMvHtv/STGNwCbdACvPJCeTciJ/sfDdggBY7mhxqaRR8vF28oXOMuzV8pVsVOucwzOGgTW+igDECqcymIP5zEOq8QwoXCPFQe1U6QjQ0wksmCokbiH7shtLsiyAgTo0wf4kQP+YSf2QhEaKy9RhR7XaauYqKAz8GTncqPmUALW+BAzw2q0O6zO/qo9u8jdHsvTVslIoQxM0UU8MU0tqAT9iQxMYrD+wa2sx5VWNwUwMFUI0QNUgsxPASi5oahvJ7BckXC6og5ksgXzMjr950xI0EFsqXKUSBad0M6iW4ic/ojh/AQOADSMJATw0AUPGDMbKLKRRmMKC7gr0TwHAa5iZFVrx/08jrGM7r4Wqupi0tNwqQ0FP/A/KUU8BqcBbLUCVoEIZNCsDOcu4AY0n//LjHfRHLsKw/oMBUapHdo0YfE0SnIjOspo8u6ieSEDwyJPEhoiQ2M5/DMDC4DKPKNaOZMQWBFlD2OcSPNbFCkfBaCx15fRbT6SdUMQYOAduIEY+FBRMWk62ZU4X7MO37W0upu4K+PRsdLNhfwFQUw9R9yMJJFtpRXZXt9kWSF1L/AlFTFah4YI/XvISN2J3wcIRRGIjd07VENrK0DVC4DVIkuwUHFc4mYBkB3cVJRBCqMgQyIVHQoOy7MgWvTJBY3I450BCFE50zzEO2LYVCBRq40VFwP/r3VrEyg0CcIOIcSXU4+SDEeQGkE0us212e8OgTstiKCfvUsfyckexKb9Thly0hIeeLIOzQXM43UVzhbv1hy+fWN70QFN4D5YyhGce9X4YW+ofH0fJDSjcNd9Wjj71KmPzWjzpKn/IpYRCi3t23sFx+fbe+db3dlyFQxGWK383Lk7CX3DQP5DDS78rmtF3iRc0Ev9lx1QCXri0SjZLe/CpCHyqjWBUFSmUjETC6+iTj4i03my5ezP3GO5v/naenjT1U5fBx4m1W7mXQ9DqW9TPsJqLRkNBmxBaJEQAreTIfNNFBGi5KHp4l1fhAAelYBM2GQQEBvgCz0GEkSUOwjr/A608wT41esuMQMkQ7T+I6Spe+ntzoQNvumwHj9kyhxoMd9wkTnv0DJ8QQAH865hwNV9knAMEhAJAbCwQuYlX4QXfen5R96BFCyqM9yswV7EdDNm+RByJzRNES2/BgwFBI9e6Go6TpZ1fOGk+4LRz1z+oRd8t+IFv0eHyj0hNFoKgy3kxTv+0+t6+Oi08O6ZXYQrDu7owQE14zKzf+RjCcML3CmLYi8O3+x3esMS/YMHT+iASp8azIMc//BgOMSyOD/P4F8VtMwwY6Q3YlqxbuBFj+IY8Z1LGAAM8A6Xq+AnMBUB3bBLEegxMaYVavMxv4hODfBv9FHtchU8rM0dX/w1aoRVKO8EDrLTsSMaYK1X/tJxLGBiqnLkUdXQ5ETOruEo0ohVS4dfZdja0p3GQCukQzI9ZL8C46M9UM8xWp4xXG2zKBTpZm7WqqEBaz+pa+/MrYI05ozNfsDPLgcqwRhVO46CLvz3enECivayjLbTt/Pa5ZoGoXzbXZTZ1NHhGXtnmExVEZ3RjubLIX3zl8/IJKMbQCLja4TYkkGrtE0SvFzegrVLpm6sUhE0j6TY2xNHLSr4rUj7si88KxImYSATLXrd3577nbwHakfe2o3cZqHc5xU05spphTX9296PX5lfRs6Ads2ccs39q6LnWJoFB1D5/4zdpNzZ4D3gV0P+7gcMXCCTKsAgC8CiKgwADARADQNPC2LgwMyoPglPACjTRQMGoKQGCwPIZcD6n1Kr1is1qt9oo9wsOfwMDk/mMTqvX7Lb73R5IxbTAiY7P6/e2OdXLFyg4WAVIeKhnh7iI15R4xxgpeeVoZTiJmVlzqdlZB+npWYmnGGpKOPrnd8q6x9kaWaq0QFC78LQQAcCQBMuVKibrO/y7CmVMnHz1qiwoTDPgYNKrJMME2jwFHPac7d23jPztzTxOiq2jxBCdEDNjApDgMJCU0Cths7TQMPCAAhPD34MBDW7ZIyDgAUAC/sBsA9PNnLKHSspJTGbx4hh0AyTUQsCgAQICENz/XQMAgQCCBkmIPMCQwFoNEQkQvAhJg+UDkQkgjMTQIOEMFw2/UOQSUaOvo3XEKfWV8WmWbtFMJGgAkIQ1EwuGEsjxQpoECaAklBFQBgDMngAaSBOQUibKBGzDMO2CTmqru1H1hurr9w9HgOl0bBUgc6vZlQ4IM2lcq50Jsi48fpQrwUEEfHadbkkaWJRnAIBDYyptetPgGhJ0ISh5WG0LAfgWKMDXQMESki0AGIQAQXIOAAhiDiUOvLfD0VPPwnkOPbr06dTPyAmXGirz7KqfvKiBwIEKf7FTrOgNc9fxGjyONHRbI0IP40o007mb5UCU/fz7+/8PYIACDkhggQYe/xjAAdhxxwpq2YGWTXD3bcegaQ5WOMiFFublDQMONEIhhn5pKKIrIT7IYYlMnKiiRiS2SMeLI6ZYIn4wPiXjjWOwuOETCZDlmCDrgbGActBoYaOOF+WoZBc8htZNBAwQ4EMg3wFABB0R3JIllkg+2aQyTIa5YJOgbbaEUBGEd+U6DrRjD1r49CQNlgN96Bs/oNhDA2cnMBBTAQK0dGcNArSTJphkDjPmoqqQGVECEbCwRAFJNNBAAguUFNJIsKX0Wk23DXFpEhgUyVkNLsFkzQsJFEAAl6XSAOsTSTraTKO4LqHrknmN1E+lNtxBBFbQ0DLUd1dmCQ8EEai0RFi0Uf/2XZfM0njrrsT0qi1piuoFmly0DjvulS/IpCxA1xInQQMYGEnbAIzBUK2q5FaRbbewcKstv+N0A5AAeNp7kpetIWdSOsF6eRJAQsxyW1u6pVNAb+sygagS+erb4Lccb+IxjujkpoBIwhZMRHjjJfxdCjOsS7IuS6S3DjQw3KDLxbUm+vGSIX/s7zcQirhxz54E7SjS2QyNYdFGa6L0IghOTfV+BhhQddZTH8J0hU4/fdrPnQhaXdlmn312l87QSLTYu+qn9dRXx121gnmoDfYTePPRNQ2E0RVPxhJ9DbRzaB+OuAnX3Z13FXu7wrYSXcLDi62Rh0I4x33rlTnDjev/zfXl45JbCwoDBHv6oQigJUALtfAiAaIM3CJJ591uLlXnj3++ex7dbIoBNbSakRZXPvHpQGPhnSAwExhIGcEJCLw7ie39is55yL3nvX2MIxdQAAaV1kJAnVZh4NG94tMgPjzxcDpwJNbvivtTuvtoCx4I0M5FkXz477eZpGoBggOAzEBHiG44AHwlkZyhmHeCBNzgHcSyl/vawgP+yc9tuKqfUu6XpjLAxwrimsUBt7AlPlzJcxEoCgaO08IyCG90T9AABTbwAW6gIzwFOdlJrNIOBBBBADJrAHlycEGSDIkR8+sg9nKnPcvRQAivS4KbJAMBxJiuh3xiyDxgUDom/9hAgvZoRwROVxQarK4MLYhTR6JFmC4dx0MSgoagpqC2CnjAAhwAH/h0uIXJQdAISIjHCBbQldPd4oIoSeMGP4eXLNCCAAWkAgBrECQs7GOJxdDD3twHgRI8jxciIckuhJCAnRTHJ1sZgKZK4r4sFaAMCWgZcgRnvg+RRCV1tBnBHnBAI6LJgAMZFOj0cwE/KrMAVTPAEwdRF0wIAGt0o5rdUJSFqhTyCimU4xdCaaTleNJWZYhGwYzlAmTl5C1xoeC4YknD7xDgjBhwzPrUwjLHrDBLb1Kj+GyjhBM68AAWSOYywdfMZwrCATOUHzWreSCsMahr3xFiDDAVMILcAv9QBBBUEk4QOxrMjgnRMFJHB7XG1sWAAJWjRBTT1BhEuc9ctUiWZVQSGy/B03MvSMEtVug5IqBLn3EkzsR28cIBFKCSCKSBHjfQRz8CMkxNnAoHG3S57yQAJsHpyY9ysAB/uApWXAKAAzgDk+iZTgmvilUunSclLIBQY6Bw38FeE4OJCWA4xckpEQ72qngixDUPq4ERL5pPutJgILugxmENmCrHUcGGGcghRBQamqpiIWpQy6o0IMAAyjBBAjwYKcXstaldfAgDZsBblu7ZPtHN9YGKJY54quQCehhwPn5FzgAiIMsavAAIBCksDRJJgsSCRzyKdEFvplcDgF6he8H/wB75YpWHTGJBu0a56ma9awqKemQ2d4DHPLN42tG9wFiwIt/JrFUwub5USVfBA3WnmgWyGRMPnJyCufSg2TKlhqKEkS4J/MfYallMpANo4Bt9c7LDfiW+Lh1nkxBp39AFUgmra0GH15GWXexEJHLKhxs5A+IIQsB8DO4nEwpVYaiB9y9ZdcwNFHAClyngpzdTQM5qEDw1kmw4BEPuImU7X0gSLEPoAN4M9ZsEs1QmBi1giQvWJAEhhMpLu9wytFgChPQRoVOmxNKsrBBgS8z4aJi9yGyV7Lm1PaEB4LsnrchHO/HgSYINPoE8kzWExPIZvctqS1bKSmFtrPlR3PGg/0berOT7XvYJCyxAA5dcgwfUqif+gMeffSlUQHP6JIWmKcMYqehOcDYTjnZzkuEs6Y08gYcajPP7SBKTidXp06cdKpVosOuG/NU1DbwYvhY9hVWfps2D017ing1txMUaKdib5enWVCUeqIwgfgYjoLn8beYGBQUj8JLKcGtsKqS5EMhmNbPN0TmIynve9PaPhqnabl7lexKtznDt9g1n370biqoGeBgKYIAOTGCz2ENLQRbQix+9+LdsgoEbk3BSjGPUBgNZ0xdtW9IvBVwi/c5ewcehzA9sgAIaEIwW2uWbH1CPiGZuS6ZSS5IihbKtBOyqhCxl81e2BR8PqPWxR/9ujpITHGoPrbe8Dwo+DljAA7wSXWnznISf3yvU5MqSaGlz6go6wIhMVbfBkT7pLOxvJhlTiBqDZFpYrJsKcHP6vKGOcIVXfQvnPcGmdjI6eMoEHhcj/NZF6oB6ihzt5BCdXC6ogN5IYGfz3Ayl9nJ2iSjzAha4JhREh+BkpSTwFZTJjrHUAgMjWvA0UGsW5s74c2jh8XeQRw2yOLCO9pIVsNcLBzbggQowXAs6ph0PCCb4F+LYBj5mggoqiDLnny6cR499rpoMgSBj8jjua+FxI7++ymeG+qKxfkWYzdDt9veR5sfI98JXDe7fAYa4KUrcMd/+T4ghmiRcPxMzn3//hYAOlXZpCXMSwHR7I7Bi2dB7MKJ039CAATgVOzR2GvQavfEwLiZd0NUMEagiD+gNHiiBloA9OiY99GdYjrQUADhRbLMSRscF2jUkKbQFLWV2I7gvzBZa9sOCjcY2YEcHr1JJeANUcoUtPYiD+icGP8CDAQghQLBcIfYVQVF2j4EOlvJbvjSFC7Fx8TAPIXaDSXgKIPhoSDhgNPIAkPAw0UMTQMBdAEAWkXVnQ6cDXmWHPtcOGXiEYjiGA9eE+QchWuQbWSQwHSEzRZgmeOQ3M/ACXzcW5SUB0oVqPMOHNDYF+4AAIxFGxEE+ygEStFFJJZAQdPCCeSCCIhKIC0FF/7EyU28oRgjUKghRXmYwLIO3h5XIZv51CyRBRBLCi3BhcTjGUgVIUgpRJ1eAiL7hf69nhj1SBS01PbQTVkPxMBJnK4oIWTqgeqo3PS3gemGIi531BOWziK13AraIQeAxCwXojWhkAxpFJ8yjUcDmivLlhDRSS9HVAycgHw4wepmhDXh0BJTyHTdWXs8nUiUzbtUXju72BM9SjulIJQzhSqinbgKFArcEc2EVZgSwkQ0xTyByj1fQGFTQGxLSQ9dYfg3pkNGCSS/kLH5DiGnRO5M4TwNQT1fnSzopXCIJiGzTEzAIAUfQCxgpUpjTjCNIFdvHBMMhExYVSlSAE0rgU//p0HeFcZVHMiEjqSKnGI4KhCgyMW4ykVp7JXkcpnjxkIaEFSstkGD+EHpFED/i9JMt4pW42A0McAdPiQQEkFSnJ33mNAu5cToqEQQM0QO34DLFZwMN1Ul12ZVJKYEREXnKAIU+2X5k2IGSyZVLkALkZwpAoILd1Zmz9wDzYBBT4nf80BAOp5juuJcWp5p5sjCdwZIt2SR32YJGIS8LID5+SYUKUBONCFZFdzwtQTpAcSjCaRP1yJC3GQt++EGcCS7P1IoyYRaKMyhIYBDooy6kMxTZyTpioJt8qJnNVpqvN381ZQOQQUkxEAHoJUHlti6D555VGGPQGZ1kUp7Y9Av/0vObXuETxxV6gGNR1FMniTGgEMYQpKmfsWA40SahZrM4mWmdQ1klctEePlB8hBRlQzmWc9QD/mBlj/mgi1B3dqeidON51lc/kygJxMiMJ0qjI/ei0skF1miiNcqjeXOeydCfPSoIGtByQipwdkmdRhoMSYp0P6qVdMAARrmjSjoiTGqjOOpDdIBO5GmlVPoZXQpnJTcQKekmWbJJrdlxFeeF8xgPy5ifXvoUB3AAG7ABcgqnsraEPOETqhRYbVgtl3JzJaEpgyhcoDmjd/oUUQU+loWoE6il7PQVwgaHZ0GTh6daSmUozvmcjWoOG6BMGcCpjioGHdGJhSYw5NMO/zpjQP00OZoKjqE6DhSgTB0Aq8vAbHulRpIiPUK1oKtXQcESWMCGn29aq9lQAcq0cMXqcloyHzZRBlmyof6gqpvyW1lymVyqrONgUByQrcvagY65BUHarVVgAeCzAeP6edlwfJiJrsTgAeBDAe16fkgqr8oAPsJXr6SBpRMBpt1qABeQr0pYI/2arQFgAQGrr/SKsLAwAVQXsGQwoRELHRW6sBV7Cim6ohk7IC1qsR3rseaHsRorsnbHsR9rsskWoRKrshJKsSfrsnsHSeL6stDppF5DsDM7mfvaNjjLswkbszfbs+ZXswwis0FbiQDDdpOwdoewtHRptCfbDYKUB//JqA9Sqge5MI5uWrRPm4RRS1tbtIunSQIwlmLvw2IrtVK80EX8cHmG0nFqNA93MDsesUkRlAR1ywRZpBLz0LbgwLUmG7XEk2N6ukaaEmRW9mUM0JFhB1dTMgMEBIdzWQAkig9r6Gd6eyoIgA/WkLn4wAOU1ABEV2tb+7c5qzfkUyduYQIpsVPwMGjdRnoFYw2aS5gnIwObYgLzUBjOAi3WwLuuMxRj9wCVRLqlC5kORC6k+hGteygQ0Gmwy7juYw23ASy2+wKryGNq1C7vMrvbW72Il5aGArTGG6ZXSFu4ShwSBH0m8Gtm5WcNgaAQVI4Vox4nsxnReFxYOUXs6TD/tTAxAPGNfku+Feu19yIfR6C+sStuOVZuEgCi8msSDDCUuis5A5l6+1gYMWMSGpxbejkC8kKJA7ywQ0sI08YHxSvCjEfCg2DCe4DCKdykOts04wvDYLPCqfHCNVy+SpbDOgxJN2waPezDjQOxK2vELEvDQ8wxITuyATI3TWwgJavEU8xuVGzF4JLEVzzFckqndqrFX5wNiloAjArGZewLnupHoGrGa9wKsupHtMrGcRwKx+pHySrHd5wJ24rHe4wJ5VoA58rHgbwI71oA8SrIh1zCBYCviMzIe/CvjQzJiXCwkUzJYdCwlYzJmazJm8zJnezJnwzKoSyvFADFpWzK/6eMyhpryIxsABuQyq8My7EsywCyAQYAyQYgxaF8ALbcyLgsylOwy7ecy6AczL08zJ9czKx8zJ6czIjsy7+8BM18yM8czatcAVfTAcv8BBOgzYHAcgBwTS2MBV6sBESqBRVgxzVAzXkwAYtcBTbUCtIsyOtcAxfwAUXaAZNswgHAAQb3zfA1COQMMlogz/RMBwZdQ6tsCvIcyAY9AZwHxxzAAQZQrhQNABRwAZxHAwbgAQaQznO6CteszhVwzf+6cBht0hfdARswyQCgAedaAaAa0wBgARMgqxZdABZgABzgzgCANf8qfA99NcLH0R5dUP180fF61E4g0R5d0hdw0v86zQG0ikMGoNCtvNMK8tRRvdMUINXCV1BDPQEfcAG2zMsUEK8UsNI1fbAoDdU0YAEKjaK8rMxPYAEKB7DeMjoTwMsrhyWd19OvkAFpDaoZoCAawK346gGgys8ekM4fUAEUwAHcDKq+bC0td9eV0nIGCwA8fdHnmtMH4AF5vXBRcACkrdcAYNguza0BANM5VNDxutiqfditDdMFgNm0iq+Z/cxZ4gWNzc22rNhqHNeTwNB8bNAc0HLKndq+PdE77QS78wrBbNlXYwBEMAEZ8K+2LNgHMNhRQKuWTTCckCW7fAAfcDVlzTAVwAEZEACbHQDs7d7wTSvWTQSAQAQFrSD/wYxwV3PfUuDbTtDR0O3TdhPgqR3M2b3dnXDce0zPY301U93cddDSNKRvU8ABHsCtWOLOH7BwwfwKHRAAlZ0BCyfeo0PeNLDYp52lBNXaUuDize3O+A3OdK3O+23LilwRAN4UE+DZXtDbTYHgtuzhNc7gNj7NLZrZAPDQqX3PFYDYCnLJ0o0MsmrIFrABJE2rHl4BOp3a5fwB8boBee3LT84w5K0BMR2vF0Cr8JwlNs3kORQFcD7WALDSANDlWV4BtErjPo7nSuDLwYzlWj7h3uLjUC5Rgy18k60BEgUIwczlXk7Tco0IDY7H9LwBRarakW3IHe0EE1DLG2DiU2Dd/0ju0mTcAdjM5AYw2G1N6ZsOzpNc0wDg6T5NA2hdKbVsyF3O6lTHy7xe4kkN7AtXAbXccqmecEm90XXA0Uow6xMwychOq7hu68pOAa3cAfGa3aC6yxuQ7crO5AfL160O169OCJZ+xwjNb80ozpWI7nKs7pKQAT0dCqbeo+8ex/FOzPaO3N28yfjOxvquBOT8zUpQ8FtQUIDsO8Zw8FxgAPTOBe1cB1TQ8N0C8Gss8AO90S1a8VfQ5HzD8Jq+BRqgxgdtN+LQ8W/D7w5esgcQ2HPgy0UN7Sb+1Uxe1g+vBFVNAaN9AVmu0iytBEJ9ATZU1m/tBUKvATUN7XDN1Rzg1f87ja8B4LAFdQFOIPNCjfNFL+5kbdZMvgEZcAHETfNQb/ND3SQXb8YGnUz3vOM3/tcub9m53dnCd0MDz8s/zucZ/tjEnuYqzthOUOSILqe87Muujee4TdNwnNcdoMYLF9rsTfcwTQNvHeSnLXyUryCIn9meXfdKgvZlTM8H4Ed+YAgnXuBnniDoveA1EMzFDOKr0MwKrt6mbeO4XMyFz+N6TVAbj7znnd7cfTUfoCCVT/jDn/lN4furryOfD8b0XAEfAD6eZwgXcPy8H+AsDsy2/PHe/eU0gP00UOSv//0FfvsKQuN6Leob7bCjM/6Mz/vE//7Vb9p5TSbM/8UGrQH/CbIEiN1yIHBwAFCQgHGUZBAAVwdo1AkcBskdVUa3dc5jm3wmFQvuxxEeJikNpyJS/VaAH45EMVQqNBMJJqN0MjYdoFdZ3UgplAr8E8+A9js+r9/z+7W2X6DgIGGh4SFiouLdm99BhsGGhtuJxQSKFs2RQYbQyYQFicaGAQ0AhWnNqIFFhVNPKKoMaaslQIdBgK0s5ilqzMlWZy/A5jCS7uVEhhkOKImtbZassefiNTYQYDZ3t/c3+HdjOHl2xmR5uvri9rr7O3x83rh8/d2lfb58u36//38gegAHEixoiJ/BhArfCVzo8OFAhBAnUkTU8I6GFhpT4VERzoiNLIUo/6ATdIHGhAsXO6p448IOPzDs+hzwWKPCBWvXJFbs6ZPPSiBSDsBoskemOBXLDpEcROHlMEE14Vy5ExMb0jxT7eDkxvMn2LBubP5ZY6eRhQsnAaQ0wGFGAVY1KFjIwIEGBZUXlFkIgCPvhVATNmS4YIaIylNsVb6tYesZKL8ALA0ubGaxAS5ALqxBbKDt2soXNmxBI+uNM700YiKJglmzhdaPDIcxEPhUXEuhJl+yQKGHrLSZzQbgqOir2OQVG14o8KHkiTcdXr41IKTCpKxXNhT70IWEBzMHPnRokoU00TV7qUa/Dv1Nm/Hl4aR/cck1Be4nNFymarbCBzZw9gIN4f9d4cIbJvwXYEyTWBADftyVAoAHA65n1npgAILaEz+Y9SAJg2WDnHIlOiTQAQWo+FINqKlkwAcHdMCBbyRoV0UKy9iGAyABcJAZBwFs2BJZM9bYogrxiZTCkONlltgJB7D4RgWkGGDCkCEdSJWCVmIpko0sCPnBkzjAl4VLmcVoRZaN/OABkFOOCKaJdUIkEIAqkjUWCjqNsdaNL+1VhJY97kZCm3vOsFZ0SfK4ZE1o1nRBR1OqkAEwX/LZBhZxpJGpljXIISSlSIaaQhl8aigpey1M4FoVxLBDp521JtRQRnvyWeEkHkzQwSSYAvCcWSxwJ8KwRiARKhRKeZClGif/APtpDRt0sEmo9LFKB0c8NEotBZpSxSmCngobbrZhbsntuJKmOsWwGmAXBbxuBvAqdrmEeOistvqrUFB32EIhJK2Epy+FCLOQmSRscUIXW4cOFskEz/DGFjMnHMyiKMxAbDFvFttSDRAGoDMyJHBGDA1fvlyMAw/WOcNvL9QgcUzLFyNjC5wu4JLMxS5vYa0pG+iKCIn/Kh1PwNnECtYjS+vhhFe0Sn01PE1jw4tYR2J9Ag/4YJP012V3o7XZaedDttptH4K223Grw7bcdQN1NEapNJXNRVnt7YjVQoktCNx8cIwRB5e8lJZ+7xxOgit45GVV4HZb7gfc2xSO+dF+/0PHR9J0m7rI40AYzcJi9ZT+VXEwVX457PMcvYM2kL62RmxuzXZZAGq91MGLl7jku41IDChNa8VCo9ZqMD95SQVPerABmb9sEErvF7yUi21rRKK7w5ldQsb1kzGPWWOpuQWdBksCQP2EIarG1gYbjOaGX8f/RoET4p9S110iJhn1rQV+NEgLo7pSu9gxkHN2aM5z/kAmNakgQigokIUqhqaKlQo15nHDJQqwBl1wyUHAIMF0cqCBNmRABVCgFlt6tAQNgrAEkyDhhAzUQhuYwUe+SiEAquOeFVinGNAhwwnEBTbIMWhARSzADUORmQPwJ0k95A6ApEAeTy0oVEBsTP8aPie6BloORSoqAMc0V5MJJuZMY6mCRrZHJDi6YFVcElOLXhSjNsQlMyZASo9eQkc2mclRVlgBjvQoIxqZwgRGMo6QkpiuYngpVD+wYyNkYgIcRUqSVfLjqRTJgj2NkYx1w9MH9PQHSBGlZIaEQwd2E4DpyBGWsowBGAyUIDy2Z5UlUJ4Io5SFKsSSBbgETzMM6R0SBAhHflrUF0SRF45EMkz8EBYbsgCiXCaTmWZppqAmsA0TYFNcRQRCNYVpynWeRVe5WiCf2OVGOEBBA/XEV7Po+ZZ62pAHNNjlljR2gV6JEwcW2EAXYlA+DfhqBBWoQj35CUV/tut9LggAd6r/wCsK/SpYx5wWNsFzQiWS4FxY4oxE5dUD9mzgohk91gjGCS4TvKoYG/VVSZU3SXaaEm4gG9nNhPCY3djiETtMWO9UUFRmeOR7ppBGJoBwsFZYDBcGiMFDKXYF63DNqB4pACme2rKsBmANXJtqBTZGCbXepFSYABnkUsYjDjDVRmFlGeT8UtatRmISIIOZXBcmBLTKgFal5KnaNpcNIUBBpwrRzjpmOYir+OFpijiqLxHLTsVigxQZGNyJ6hE2QcBVVnvgmiIg5jrNbhZvrH0t5WBLRs7Kdp2Hre3S4JaRFvhpEJAFnAw+F5HXwe62uP1X5i5Qk7Q41g+/pUkSSvcP/+OajbrHrdVFaJfZW3Cnf5/5n11QUr/7WQGBeOlA+SrRsjZw4EcTIJ9v9DI+tcDMfjmhn2VYQDwBZea818uLbcYHwNUYhjYdMAUSL2fd69aJOc6BzjYqQE4rbqc7UnCiEBxJnYzM0FRKCqgPQUKwX7LlFi6oQEwzSDUUXGKZPwixWQyEUQvXZy81DSJo5bZgBpfIjCva7go0GVAmDbOOKFCkZStKLl7qKDGFiWQjiPxGQQqpyAFtcnTHkqgd14nLPBYLKlWpTkSZYZnDCuheALHNPtUgyW5cckAJBYhfPScqnxlSMa9QHitXQc5Ztk+WfkOa2Hn5y2DBVToRlQUPJP/OohWeMbLSI1EKDZSjSbYWttqA3mL0WVlJ6ELifiOFmEoqoo0pAg8u+hJULwvSpOZTEEdAaOIaWmo+zQwr0EHWETJsEiKoay/QitqOwWJln5yBKV4BMat6Ymh+JeolvBqiDNTPBbxQNvZ6vbKgWYuBha51T2ibh6d9ex07iJ5reZkHFDdXx7QGN3LTTQjUlnYizObDsO3ggRMW993wtpW4/922cgv8RPIuuIL9jfAeH1wUGsmx/NBmT2z8YCtAEPEfGh6IJMuuD3/7RLsrQvCFGyS5B2D00aLSB44bouJHa4jFSSddRjT847AWy8hJTpDs6jSQxXieZ8wXmr6Aqb3/n/EuaGNjF2W8aA1EcYu1D9j0oPsGOCjRy3uSd7vJAFBxkOBADCKThP0OT3soDB5voucWX30ASmHJuc4B4uAIqlMDyk2DC0cgnQ3LhyxV2GHUWkTgIJqVOy5WdTGgEYMod8gFhMKOqExI+FNIaPAzBpANtrji7+ZogynhUwpIWOKAAwTucfeHj9EoQRhlCtcmcBEFEVIFIY+uAE7akc/fFCf22Isno7p9G78aUHENMvRU5iR9OIBp9uBc4af/SZht78sKrSGY3zqnou3Q52+6sjutHPOL7wWrcsG6Bd+3w+/dyifMz96Lt7SlMZFPpfBISOMLMf3z84FoUg7TDAdN/yhV3FRB2cGmVYlLlYwPcAe7oFoGqBo+6Uu02EsQMcHgjMoLxEAdTMiMtR8gmNokPME+vQU+oUEKPMstmEG0NF/+xZsf/BQNWFUMDAxa1dux7VrJQMJekcwyEI3QRMKBYYz/4YMsrEIrtEhUkQwn5IJZmcLMRAmwLdVR9czdUQYpIBQQJgf+raA8kF45cGE4eKG+yYBrLE0WamHW2F88DExBqGFncQLE1UoZmqE7gKEcKkcc1mE60CEevp3z7SHAoKEfwmEfBmJB6CEhitwgHqLcAaIi2mEiNmI/REIcTSIlVqIlXiImZqImbiIndqInfiIohqIojuImkgIk+sRTkEKiKq4iK7aiK74iLMbiJBrHKdaiLd4iLuaiLu4iL/aiL/4iMAajMA4jMRajMR4jMiajMi4jMzajMz4jNEajNJJDCAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Urinalysis.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Patel, HP, Bissler, JJ. Hematuria in children. Pediatr Clin North Am 2001; 48:1519. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35504=[""].join("\n");
var outline_f34_43_35504=null;
var title_f34_43_35505="Osteomyelitis soft tissue";
var content_f34_43_35505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early osteomyelitis in a 6-year-old with fever and ankle pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Plain radiographs of the ankle demonstrate deep soft tissue swelling inferior to the medial malleolus. B) A technetium 99m bone scan shows increased uptake in the distal tibia in the blood flow and bone uptake (four hour) phases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin B Harper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35505=[""].join("\n");
var outline_f34_43_35505=null;
var title_f34_43_35506="Identification of the long thoracic nerve";
var content_f34_43_35506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Identification of the long thoracic nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both index fingers are used to spread along the chest wall to expose the long thoracic nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35506=[""].join("\n");
var outline_f34_43_35506=null;
var title_f34_43_35507="Chorioamnionitis 3";
var content_f34_43_35507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chorioamnionitis 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35507=[""].join("\n");
var outline_f34_43_35507=null;
var title_f34_43_35508="Homatropine: Drug information";
var content_f34_43_35508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Homatropine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/46/7908?source=see_link\">",
"    see \"Homatropine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/24/15747?source=see_link\">",
"    see \"Homatropine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Homatropaire;",
"     </li>",
"     <li>",
"      Isopto&reg; Homatropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent, Ophthalmic;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Mydriatic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with heavily pigmented irides may require increased dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refraction:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% solution: 1-2 drops into eye(s); repeat every 10-15 minutes if necessary; maximum: 5 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% solution: 1-2 drops into eye(s); repeat dose in 15 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uveitis:",
"     </b>",
"     Ophthalmic: 2% or 5% solution: 1-2 drops 2-3 times daily, up to every 4 hours for severe uveitis (Alexander, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F179261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/24/15747?source=see_link\">",
"      see \"Homatropine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Children (&gt;3 months of age) should only use the 2% strength solution; patients with heavily pigmented irides may require increased dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refraction:",
"     </b>",
"     Ophthalmic: 2% solution: 1-2 drops into eye(s); repeat every 10-15 minutes if necessary; maximum: 5 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uveitis:",
"     </b>",
"     Ophthalmic: 2% solution: 1-2 drops 2-3 times daily, up to every 4 hours for severe uveitis (Alexander, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrobromide [drops]: 5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Homatropaire: 5% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Homatropine: 2% (5 mL); 5% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F179235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic instillation: Wash hands before and after use. Do not touch tip of container to eye. Contact lenses should be removed before instillation; do not reinsert contact lenses within 15 minutes of drops. Finger pressure should be applied to lacrimal sac for 1-3 minutes after instillation to decrease risk of absorption and systemic reactions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Producing cycloplegia and mydriasis for refraction; treatment of acute inflammatory conditions of the uveal tract; optical aid in axial lens opacities",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7727193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Homatropine may be confused with Humatrope&reg;, somatropin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, irritation, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, eczematoid dermatitis, edema, exudate, follicular conjunctivitis, intraocular pressure increased, photophobia, vascular congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Thirst",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to homatropine or any component of the formulation; primary glaucoma or narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Excessive use may cause CNS disturbances, including confusion, delirium, agitation, and coma (rare). May occur with any age group, although children and the elderly are more susceptible. Patients should be cautioned about performing tasks which require mental alertness (eg, operating machinery, driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Light sensitivity (ocular): May cause sensitivity to light; appropriate eye protection should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Down syndrome: Patients with Down syndrome are predisposed to angle-closure glaucoma; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Keratoconus: May result in fixed pupil dilation in patients with keratoconus; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly due to susceptibility to systemic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in infants and young children, therefore, use with extreme caution due to susceptibility of systemic effects. Avoid use during the first 3 months of life.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some strengths may contain benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings and precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical ophthalmic use only; discontinue use if pain within the eye occurs. To minimize systemic absorption, apply pressure over the nasolacrimal sac for 1-3 minutes after instillation. To avoid contamination, do not touch dropper tip to any surface. To avoid precipitating angle closure glaucoma, an estimation of the depth of the anterior chamber angle should be made prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5630948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F179240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Homatropaire Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (5 mL): $20.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Homatropine HBr Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (5 mL): $25.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isopto Homatropine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (5 mL): $39.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (5 mL): $46.08",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bromhydrate d'homatropine-Chauvin (LU);",
"     </li>",
"     <li>",
"      Hemasol (SG);",
"     </li>",
"     <li>",
"      Homarin Forte (IN);",
"     </li>",
"     <li>",
"      Homatropin (HR, NO);",
"     </li>",
"     <li>",
"      Homatropin-POS (DE);",
"     </li>",
"     <li>",
"      Homatropine (AU, BE, NL);",
"     </li>",
"     <li>",
"      Homatropine Faure (FR);",
"     </li>",
"     <li>",
"      Isopto Homatropine (AE, AU, BF, BH, BJ, CI, CY, EG, ET, FR, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NZ, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Isopto-Homatropine (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Minims Homatropine (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Minims Homatropine HBr (HK);",
"     </li>",
"     <li>",
"      Minims Homatropine Hydrobromide (GB, IE);",
"     </li>",
"     <li>",
"      Minims-Homatropinhydrobromid (AT);",
"     </li>",
"     <li>",
"      Ocuhomapine (KP);",
"     </li>",
"     <li>",
"      Omatropina (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks response of iris sphincter muscle and the accommodative muscle of the ciliary body to cholinergic stimulation resulting in dilation (mydriasis) and paralysis of accommodation (cycloplegia)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alexander KL, Dul MW, Lalle PA, et al, &ldquo;Optometric Clinical Practice Guideline Care of the Patient With Anterior Uveitis,&rdquo; American Optometric Association, 2004. Available at file://www.aoa.org/documents/CPG-7.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barker DB and Solomon DA, &ldquo;The Potential for Mental Status Changes Associated With Systemic Absorption of Anticholinergic Ophthalmic Medications: Concerns in the Elderly,&rdquo;",
"      <i>",
"       DICP Ann Pharmacother",
"      </i>",
"      , 1990, 24(9):847-50.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8525 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35508=[""].join("\n");
var outline_f34_43_35508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179245\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179269\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179246\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179261\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179247\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897523\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897524\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179232\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179219\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179235\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179233\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727193\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179267\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179238\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179223\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299448\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220810\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179229\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630949\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630948\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179240\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038652\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179222\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/46/7908?source=related_link\">",
"      Homatropine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/24/15747?source=related_link\">",
"      Homatropine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_43_35509="High frequency catheter endoscopic ultrasonography";
var content_f34_43_35509=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   High frequency catheter endoscopic ultrasonography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35509/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35509/contributors\">",
"     Enrique Vazquez-Sequeiros, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35509/contributors\">",
"     Maurits J Wiersema, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35509/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35509/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35509/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35509/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/43/35509/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) has an important role in the evaluation of benign and malignant gastrointestinal diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Echoendoscopes operate from 5 to 20 MHz, permitting a spectrum of depth of penetration and image resolution. Higher frequencies provide higher resolution but less penetration, while lower frequencies provide higher penetration but lower resolution.",
"   </p>",
"   <p>",
"    Advancements in ultrasound technology have led to the development of small caliber ultrasound catheters (maximum diameter 2.6 mm) that can be passed through the biopsy channel of a standard endoscope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/9\">",
"     9",
"    </a>",
"    ]. These miniprobes operate across a range of frequencies (12 to 30 MHz), providing a greater image resolution (0.07 to 0.18 mm) than standard EUS scopes as well as improved accuracy for studying small or superficial lesions of the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review describes the technical characteristics of the commercially available high frequency ultrasound (HFUS) catheters and the experience with their use in a variety of conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFUS catheters can be broadly classified by their working mechanism into mechanical and electronic catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanical catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical catheters have a single ultrasound transducer located at the tip of the catheter, which is rotated by a cable and transmits the signal from the transducer to the ultrasound processor. A flexible housing protects the cable and the transducer from damage. When rotating, the ultrasound transducer produces a 360-degree image, perpendicular to the longitudinal axis of the HFUS catheter. Certain models of HFUS mechanical catheters can be inserted over a guidewire, facilitating examination of the bile and pancreas ducts. These probes have been modified so that linear imaging is also possible with subsequent 3D reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Electronic catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electronic catheters consist of a probe that contains a number of fixed ultrasound transducers (ie, no rotating system) at their tips. These transducers transmit signals via microwires to the image processor. Electronic probes may be oriented radially (perpendicular to the longitudinal axis of the probe) or linearly (ultrasound plane oriented along the longitudinal axis of the probe). Most experience with these catheters has been in cardiovascular applications, although case series suggest that they also have promise in evaluating gastrointestinal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXAMINATION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard endoscope is negotiated through the gastrointestinal tract until the area of interest is reached. The HFUS catheter is advanced through the biopsy channel of the endoscope and placed in contact with the target lesion.",
"   </p>",
"   <p>",
"    A number of techniques have been described to obtain adequate acoustic coupling between the HFUS catheter and the lesion of interest. The two methods most frequently used are the condom and the balloon techniques, both of which have advantages and disadvantages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Condom technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;A latex condom is attached to the distal end of the endoscope. This obscures visualization and prevents air insufflation. As a result, endoscopy must first be performed without the condom. After advancing the endoscope to the region of interest, the condom is filled with water through the biopsy channel of the endoscope. The HFUS probe is inserted through the biopsy channel, and acoustic coupling between the probe and the area of interest is achieved with no or minimal compression artifacts. However, air pockets between the condom and the gut wall may still be present, resulting in ultrasound image degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/10,13,14\">",
"     10,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Balloon technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catheter is inserted into a latex sheath with a distal balloon that can be instilled with water to facilitate acoustic coupling. Although easy to work with, this balloon sheathed catheter still has limitations in obtaining adequate acoustic coupling. Once the HFUS catheter has been inserted through the biopsy channel of the scope, air pockets between the balloon and the gut wall are difficult to suction, leading to less than optimal image quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/15\">",
"     15",
"    </a>",
"    ]. If the balloon sheathed HFUS catheter is used in conjunction with a double channel endoscope, one can suction air pockets and inject small pulses of water into the lumen through the second biopsy channel after the HFUS catheter has been inserted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immersion technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catheter with or without a balloon sheath can be inserted into the gastrointestinal lumen after instilling water into the lumen to permit acoustic coupling. As an alternative, a double channel endoscope can be used with the second channel serving to permit water instillation into the lumen. This technique can be used in any location where the water will not migrate (ie, the lesion is in a dependent position). When used in the stomach or duodenum, care must be taken to avoid overfilling resulting in potential aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NORMAL GASTROINTESTINAL WALL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dedicated echoendoscopes, typically scanning at 7.5 to 12 MHz, provide a five-layer ultrasound image of the gastrointestinal wall: superficial (first layer: hyperechoic) and deep mucosa (second layer: hypoechoic), submucosa (third layer: hyperechoic), muscularis propria (fourth layer: hypoechoic) and",
"    <span class=\"nowrap\">",
"     adventitia/serosa",
"    </span>",
"    (fifth layer: hyperechoic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/17\">",
"     17",
"    </a>",
"    ]. Limited resolution precludes separate identification of the muscularis mucosa. In contrast, catheters operating at 20 to 30 MHz provide a more detailed ultrasound image of the gut wall (9 to 11 layers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro and in vivo studies with high frequency ultrasound probes have shown that [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The first (hyperechoic) and second layers (hypoechoic) correspond to the interface with the lumen and mucosal epithelium",
"     </li>",
"     <li>",
"      The third (hyperechoic) and fourth layers (hypoechoic) correspond to deep mucosa (lamina propria)",
"     </li>",
"     <li>",
"      The fifth (hyperechoic) and sixth layers (hypoechoic) correspond to the muscularis mucosae interface and muscularis mucosae",
"     </li>",
"     <li>",
"      The seventh layer (hyperechoic) is the submucosa",
"     </li>",
"     <li>",
"      The eighth layer (hypoechoic) is the inner layer of the muscularis propria",
"     </li>",
"     <li>",
"      The ninth layer (hyperechoic) corresponds to connective tissue and the interface between the muscle layers",
"     </li>",
"     <li>",
"      The tenth layer (hypoechoic) corresponds to the outer layer of the muscularis propria",
"     </li>",
"     <li>",
"      The eleventh layer (hyperechoic) is the",
"      <span class=\"nowrap\">",
"       serosa/adventitia",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFUS catheters have been described in staging esophageal, gastric, pancreatic, biliary, and colorectal cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Esophageal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency miniprobes are best suited for determining tumor extension (T stage) with superficial tumors where they may guide therapy in patients for whom surgery in undesirable. The high frequency probes delineate tumor extension into the muscularis mucosa, information that is critical since tumors that do not invade the muscularis mucosa can be cured by endoscopic mucosal resection alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .) The accuracy of high frequency miniprobes for determining tumor extension into the muscularis mucosa is in the range of 80 percent, although there have been few detailed studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, dedicated EUS scopes do not permit identification of the muscularis mucosae layer. On the other hand, they are much better suited for examining regional nodal involvement, making them complementary to examination with high frequency probes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65394 \" href=\"mobipreview.htm?25/17/25873\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HFUS probes can also assist in staging of stenotic esophageal tumors that cannot be traversed with the dedicated echoendoscope at all or without prior dilation (which is associated with up to a 25 percent perforation rate in some series). Although initial reports with this technique are promising, results have been questioned due to lack of histological confirmation of tumor stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/15,22,23\">",
"     15,22,23",
"    </a>",
"    ]. Limited depth of imaging may also preclude complete tumor assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Barrett's esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-frequency miniprobes do not appear to accurately predict the presence of invasive cancer in patients with Barrett's esophagus and high-grade dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gastric cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of HFUS for delineation of tumor invasion into the muscularis mucosae layer in gastric cancer is approximately 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Ulcer scars and dilated glands are responsible for the majority of staging mistakes. HFUS catheters (12 and 20 MHz: Olympus UM-3D2R and UM-3D3R), which provide three-dimensional imaging, have also been used for staging superficial carcinomas of the stomach, with a T staging accuracy of approximately 90 percent in early cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the largest reports on HFUS in colorectal cancer focused on 67 rectal lesions that were imaged with a 20 MHz catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/28\">",
"     28",
"    </a>",
"    ]. Tumor staging accuracy (T stage) was 76 percent (overstaging in 16 percent and understaging in 8 percent of lesions). HFUS catheters were more accurate for studying small and flat lesions (100 percent accuracy for lesions less than 15 mm) than large or polypoid lesions (67 percent accuracy for lesions greater than 20 mm). In addition, HFUS catheters accurately determined if a tumor was invading the superficial third of the submucosa (SM1), middle third (SM2), or deep third (SM3) (accuracy: 83 percent to 100 percent). This distinction may be of value if endoscopic therapy is being considered. However, sessile colon polyps with invasive carcinoma are traditionally treated with surgery. In another report, HFUS was more accurate than high magnification chromoendoscopy for differentiating",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pancreatic and biliary diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound catheters are available that may be passed over a guidewire into the bile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreatic ducts during endoscopic retrograde cholangiopancreatography (ERCP), with a success rate approaching 100 percent. Intraductal ultrasound (IDUS) appears to be safe with less than 1 percent complication rate. IDUS has been studied in the evaluation of biliary stone disease, bile duct strictures, pancreatic disease, pancreatic duct strictures, and diagnosis of cholangiocarcinoma and ampullary tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33353?source=see_link\">",
"     \"Intraductal ultrasound of the pancreaticobiliary ductal system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Submucosal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFUS catheters can be used to image small (&lt;2 cm) submucosal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35509/abstract/30\">",
"     30",
"    </a>",
"    ]. Enhanced delineation of wall layers may permit better assessment of the layer of origin. Additionally, the technique permits US imaging of lesions that may not be readily accessible by dedicated echoendoscopes (eg, right colon).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advancements in ultrasound technology have led to the development of small caliber ultrasound catheters (maximum diameter 2.6 mm) that can be passed through the biopsy channel of a standard endoscope. These miniprobes operate across a range of frequencies (12 to 30 MHz), providing a greater image resolution (0.07 to 0.18 mm) than standard EUS scopes as well as improved accuracy for studying small or superficial lesions of the gastrointestinal tract.",
"     </li>",
"     <li>",
"      High frequency miniprobes allow for the accurate evaluation of superficial neoplasms and small submucosal lesions and thus represent an integral component of pretherapy assessment in centers that routinely perform endoscopic resection for early stage malignancies. However, the limited depth of penetration requires the use of dedicated echoendoscopes to provide lymph node staging.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/1\">",
"      R&ouml;sch T, Lorenz R, Braig C, et al. Endoscopic ultrasound in pancreatic tumor diagnosis. Gastrointest Endosc 1991; 37:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/2\">",
"      Dancygier H, Nattermann C. The role of endoscopic ultrasonography in biliary tract disease: obstructive jaundice. Endoscopy 1994; 26:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/3\">",
"      R&ouml;sch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/4\">",
"      R&ouml;sch T, Braig C, Gain T, et al. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology 1992; 102:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/5\">",
"      Amouyal P, Amouyal G, L&eacute;vy P, et al. Diagnosis of choledocholithiasis by endoscopic ultrasonography. Gastroenterology 1994; 106:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/6\">",
"      Burtin P, Palazzo L, Canard JM, et al. Diagnostic strategies for extrahepatic cholestasis of indefinite origin: endoscopic ultrasonography or retrograde cholangiography? Results of a prospective study. Endoscopy 1997; 29:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/7\">",
"      Giovannini M, Seitz JF, Thomas P, et al. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Endoscopy 1997; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/8\">",
"      Brugge WR. Endoscopic ultrasonography: the current status. Gastroenterology 1998; 115:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/9\">",
"      Menzel J, Domschke W. Gastrointestinal miniprobe sonography: the current status. Am J Gastroenterol 2000; 95:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/10\">",
"      Kawano T, Oshima M, Endo M. Endoscopic ultrasonographic diagnosis. Stomach Intestine 1995; 30:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/11\">",
"      Norton ID, Bruce CJ, Seward JB, et al. Initial experience with a steerable, phased vector array ultrasound catheter in the GI tract. Gastrointest Endosc 2001; 53:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/12\">",
"      Shamoun DK, Norton ID, Levy MJ, et al. Use of a phased vector array US catheter for EUS. Gastrointest Endosc 2002; 56:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/13\">",
"      Inoue H, Kawano T, Takeshita K, Iwai T. Modified soft-balloon methods during ultrasonic probe examination for superficial esophageal cancer. Endoscopy 1998; 30 Suppl 1:A41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/14\">",
"      Wallace MB, Hoffman BJ, Sahai AS, et al. Imaging of esophageal tumors with a water-filled condom and a catheter US probe. Gastrointest Endosc 2000; 51:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/15\">",
"      Fockens P, van Dullemen HM, Tytgat GN. Endosonography of stenotic esophageal carcinomas: preliminary experience with an ultra-thin, balloon-fitted ultrasound probe in four patients. Gastrointest Endosc 1994; 40:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/16\">",
"      Vazquez-Sequeiros E, Wiersema MJ. High-frequency US catheter-based staging of early esophageal tumors. Gastrointest Endosc 2002; 55:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/17\">",
"      Kimmey MB, Martin RW, Haggitt RC, et al. Histologic correlates of gastrointestinal ultrasound images. Gastroenterology 1989; 96:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/18\">",
"      Hasegawa N, Niwa Y, Arisawa T, et al. Preoperative staging of superficial esophageal carcinoma: comparison of an ultrasound probe and standard endoscopic ultrasonography. Gastrointest Endosc 1996; 44:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/19\">",
"      Tajima Y, Nakanishi Y, Ochiai A, et al. Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma: analysis of 240 surgically resected tumors. Cancer 2000; 88:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/20\">",
"      Murata Y, Suzuki S, Ohta M, et al. Small ultrasonic probes for determination of the depth of superficial esophageal cancer. Gastrointest Endosc 1996; 44:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/21\">",
"      Konishi H, Murata Y, Kishino M, et al. A study of the layer structure of the gastric wall and diagnosis of cancer invasion by using 30 MHz ultrasonographic probe (Abstract). Endoscopy 2000; 32:A18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/22\">",
"      Chak A, Canto M, Stevens PD, et al. Clinical applications of a new through-the-scope ultrasound probe: prospective comparison with an ultrasound endoscope. Gastrointest Endosc 1997; 45:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/23\">",
"      Van Dam J, Rice TW, Catalano MF, et al. High-grade malignant stricture is predictive of esophageal tumor stage. Risks of endosonographic evaluation. Cancer 1993; 71:2910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/24\">",
"      Waxman I, Raju GS, Critchlow J, et al. High-frequency probe ultrasonography has limited accuracy for detecting invasive adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: a case series. Am J Gastroenterol 2006; 101:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/25\">",
"      Yanai H, Fujimura H, Suzumi M, et al. Delineation of the gastric muscularis mucosae and assessment of depth of invasion of early gastric cancer using a 20-megahertz endoscopic ultrasound probe. Gastrointest Endosc 1993; 39:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/26\">",
"      Saitoh Y, Obara T, Einami K, et al. Efficacy of high-frequency ultrasound probes for the preoperative staging of invasion depth in flat and depressed colorectal tumors. Gastrointest Endosc 1996; 44:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/27\">",
"      Sabet EA, Okai T, Minamoto T, et al. Three-dimensional endoscopic ultrasonography in gastric carcinoma (Abstract). Endoscopy 2000; 32:A6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/28\">",
"      Yoshida M, Tsukamoto Y, Niwa Y, et al. Endoscopic assessment of invasion of colorectal tumors with a new high-frequency ultrasound probe. Gastrointest Endosc 1995; 41:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/29\">",
"      Hurlstone DP, Brown S, Cross SS, et al. High magnification chromoscopic colonoscopy or high frequency 20 MHz mini probe endoscopic ultrasound staging for early colorectal neoplasia: a comparative prospective analysis. Gut 2005; 54:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35509/abstract/30\">",
"      Koch J, Halvorsen RA Jr, Levenson SD, Cello JP. Prospective comparison of catheter-based endoscopic sonography versus standard endoscopic sonography: evaluation of gastrointestinal-wall abnormalities and staging of gastrointestinal malignancies. J Clin Ultrasound 2001; 29:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2679 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35509=[""].join("\n");
var outline_f34_43_35509=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanical catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Electronic catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXAMINATION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Condom technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Balloon technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immersion technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NORMAL GASTROINTESTINAL WALL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pancreatic and biliary diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Submucosal lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2679|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/17/25873\" title=\"diagnostic image 1\">",
"      Esophageal cancer HFUS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33353?source=related_link\">",
"      Intraductal ultrasound of the pancreaticobiliary ductal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_43_35510="Pagets dis with carcinoma";
var content_f34_43_35510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extramammary Paget disease of the vulva with adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35510=[""].join("\n");
var outline_f34_43_35510=null;
var title_f34_43_35511="Approach to the diagnosis of chronic diarrhea in children in developed countries";
var content_f34_43_35511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the diagnosis of chronic diarrhea in children in developed countries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35511/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35511/contributors\">",
"     Richard Kellermayer, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35511/contributors\">",
"     Robert J Shulman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35511/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35511/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35511/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/43/35511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, a wide variety of disorders cause chronic diarrheas in children. The causes range from developmental and dietary factors (eg, excessive consumption of juice), to diseases causing malabsorption or maldigestion, or enteric infections (particularly in immunocompromised patients) (",
"    <a class=\"graphic graphic_table graphicRef56837 \" href=\"mobipreview.htm?25/32/26125\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the developing world, chronic diarrhea typically is associated with serial enteric infections and malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This common pathophysiology calls for a distinct algorithmic approach to diagnosis and treatment, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approach to diarrheal diseases in developed countries will be reviewed here. The causes of these diarrheal diseases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link\">",
"     \"Overview of the causes of chronic diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of the appropriate strategy to diagnose the cause of chronic diarrhea in a child depends on the presentation of the patient. In most cases, a thorough history and physical examination narrows the range of possibilities. For children presenting with chronic diarrhea in developed countries, two of the most likely causes are chronic nonspecific diarrhea and celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Therefore, it is appropriate to consider these disorders early in the evaluation before embarking on extensive laboratory testing. If these steps do not establish a diagnosis, then further laboratory testing can be selected based on the stool type. This stepwise strategy is outlined below (",
"    <a class=\"graphic graphic_algorithm graphicRef60860 \" href=\"mobipreview.htm?22/10/22692\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history often provides clues to the diagnosis or diagnostic category (",
"    <a class=\"graphic graphic_table graphicRef81662 \" href=\"mobipreview.htm?12/27/12733\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timing of onset &ndash; Neonatal onset of watery diarrhea strongly suggests one of the congenital diarrheas. Chronic diarrheas triggered by an infectious insult (including post-infectious lactose intolerance or antibiotic-associated diarrhea) typically have an abrupt onset. Gradual onset of a mild chronic diarrhea in an otherwise healthy toddler suggests functional diarrhea (chronic nonspecific diarrhea of childhood) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/5\">",
"       5",
"      </a>",
"      ]. The onset of symptoms in celiac disease varies greatly, but cannot precede the introduction of gluten-containing foods.",
"     </li>",
"     <li>",
"      Stool characteristics &ndash; Stools that become looser as the day progresses are typical of functional diarrhea. Diarrheal stools that are passed at night are more concerning for an underlying organic disorder. Stools that contain visible or occult blood suggest an inflammatory diarrhea, which may be caused by a dietary protein intolerance (common in infants), inflammatory bowel disease, or (rarely) chronic infection with an enteric pathogen. A history of small-volume fecal incontinence should prompt questions to determine if occult constipation might be present.",
"     </li>",
"     <li>",
"      Other symptoms &ndash; A history of failure to thrive or weight loss suggests the possibility of malabsorptive disease (celiac disease, cystic fibrosis, or other cause of pancreatic exocrine insufficiency), hyperthyroidism, or anorexia nervosa in the school-age child or adolescent. A history of recurrent infections suggests underlying immunodeficiency or cystic fibrosis.",
"     </li>",
"     <li>",
"      Family history &ndash; A family history of disease affecting the bowel may provide clues to heritable diseases, but a negative family history does not exclude celiac disease or inflammatory bowel disease.",
"     </li>",
"     <li>",
"      Abdominal examination &ndash; Severe abdominal pain or abdominal distension may be caused by intestinal obstruction or enterocolitis, particularly if blood is present in the stools. These symptoms occurring in a child with chronic diarrhea or chronic constipation call for an urgent evaluation for obstruction and infection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Inflammatory'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory tests are available to narrow the diagnostic possibilities and establish a diagnosis. We suggest selecting from among these tests according to a stepwise diagnostic approach as outlined below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Celiac serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, the most valuable test is for antibodies against tissue transglutaminase (anti-tTG), which is highly sensitive, specific, and more cost-effective than other antibody tests. False-positive and false-negative results may still occur with some frequency in populations with a low risk for celiac disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stool pH, electrolytes, and reducing substances",
"    </span>",
"    &nbsp;&mdash;&nbsp;For watery stools, fecal electrolyte concentrations and pH are measured in stool water after homogenization of a fresh specimen (by manual stirring or in a mechanical blender) and centrifugation of an aliquot to obtain supernatant for analysis. Fecal pH is measured with nitrazine paper on a fresh stool sample.",
"   </p>",
"   <p>",
"    The osmotic gap of fecal fluid can be used to estimate the relative contributions of electrolytes and nonelectrolytes to retention of water in the intestinal lumen. In osmotic diarrhea, nonelectrolytes cause water retention. The osmotic gap is calculated from electrolyte concentrations in stool water by the following formula: 290 - 2([Na+] + [K+]) (",
"    <a class=\"graphic graphic_table graphicRef51596 \" href=\"mobipreview.htm?15/36/15947\">",
"     table 3",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/42/9890?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). This formula is preferred over those that use measured stool osmolalities, because the latter may be falsely elevated due to post-collection changes or to contamination of the sample with concentrated urine.",
"   </p>",
"   <p>",
"    If the patient's diet includes reducing sugars, the stool can be tested for reducing substances, which if present suggest carbohydrate malabsorption. Glucose, lactose, and fructose are reducing sugars, but sucrose is not. However, malabsorbed sucrose can also be degraded by colonic bacteria to glucose and fructose, resulting in a positive test for reducing substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Occult blood and leukocyte markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests of stool for occult blood and fecal leukocytes have some ability to predict inflammatory processes. However, the sensitivity and specificity of each of these tests is poor.",
"   </p>",
"   <p>",
"    As an example, in addition to inflammatory bowel diseases and enteric pathogens, a substantial number of individuals with celiac disease and rotavirus diarrhea also test positive for occult fecal blood. Functional diarrhea or diarrhea caused by laxative abuse is less likely to contain occult blood. The American Gastroenterological Association (AGA)",
"    <a class=\"external\" href=\"file://www.gastrojournal.org/article/S0016-5085(99)70513-5/fulltext\">",
"     Technical review on the evaluation and management of chronic diarrhea",
"    </a>",
"    (including a discussion on occult blood) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/6\">",
"     6",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA Web site.",
"   </p>",
"   <p>",
"    Fecal calprotectin levels are increased in intestinal inflammation, and may be useful for distinguishing inflammatory from noninflammatory causes of chronic diarrhea. However, test characteristics vary depending on the prevalence of inflammatory bowel disease in the study population. Thus, the test may be used to focus the next stage of the investigation, but results should not be interpreted to firmly include or exclude any disease or disease category. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\", section on 'Fecal calprotectin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stool fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests can be used to detect fat malabsorption (steatorrhea). The gold standard for diagnosis of steatorrhea is quantitative estimation of stool fat, usually performed over 72 hours, while the patient eats a diet containing at least 100 g of fat per day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of malabsorption\", section on 'Tests for fat malabsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because 72-hour stool collection is cumbersome, qualitative tests also are used to detect steatorrhea. These include the Sudan III stain and acid steatocrit, a rapid gravimetric method. The sensitivity and reliability of the Sudan III test is limited by variability in its performance and interpretation. The acid steatocrit is rarely available in clinical laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional specific testing may be performed based on patient characteristics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the diagnostic considerations raised by the categorization steps outlined below. Clinical suspicion of the following disease processes calls for specific testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory bowel disease &ndash; (eg, grossly bloody stools, growth failure, or family history of IBD). Measure complete blood count, serum albumin, and erythrocyte sedimentation rate or C-reactive protein (CRP). Perform contrast radiography of the small bowel (or magnetic resonance imaging), and upper and lower endoscopy depending on degree of clinical suspicion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein-losing gastroenteropathy &ndash; (eg, reduced serum concentrations of albumin and gamma globulins, peripheral edema). Perform fecal alpha-1 antitrypsin testing to measure fecal protein losses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=see_link\">",
"       \"Protein-losing gastroenteropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystic fibrosis &ndash; (eg, pulmonary symptoms, failure to thrive, or family history of disease). Perform sweat chloride testing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatic insufficiency &ndash; (eg, suspicion of cystic fibrosis or marked steatorrhea). Perform indirect tests of pancreatic function, including measurement of fecal elastase-1",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chymotrypsin; the stool content of these enzymes is reduced in patients with pancreatic insufficiency. The diagnostic accuracy of these tests is low and is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34201?source=see_link\">",
"       \"Pancreatic exocrine function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factitious diarrhea &ndash; (eg, suspicion of laxative abuse, hypokalemia or metabolic alkalosis, or factitious diarrhea). Perform a laxative screen if available, and measure the stool osmolality. The measured stool osmolality is elevated in the presence of osmotically active laxatives (&gt;290",
"      <span class=\"nowrap\">",
"       mOsm/kg),",
"      </span>",
"      and is reduced (&lt;290",
"      <span class=\"nowrap\">",
"       mOsm/kg)",
"      </span>",
"      if the sample is contaminated with water or dilute urine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6246?source=see_link\">",
"       \"Factitious diarrhea\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exclude celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high prevalence of celiac disease in most populations and the availability of noninvasive, sensitive, and specific testing, all children with chronic diarrhea in developed countries should be screened for celiac disease. We suggest screening with serum testing for anti-tissue transglutaminase antibodies. Many providers also test serum immunoglobulin A (IgA) levels at the same time to avoid the possibility of a false-negative result in the case of IgA deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Consider functional diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with functional diarrhea (sometimes called chronic nonspecific diarrhea of childhood or toddler's diarrhea) typically present with the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of diarrhea between 6 and 36 months of age",
"     </li>",
"     <li>",
"      Painless passage of three or more large, unformed stools daily",
"     </li>",
"     <li>",
"      Stools usually passed only during waking hours",
"     </li>",
"     <li>",
"      No failure to thrive (if caloric intake is adequate)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After exclusion of celiac disease, children with these characteristics can be given a provisional diagnosis of functional diarrhea. In some cases, functional diarrhea is caused by excessive intake of osmotically active carbohydrates (eg, apple, prune, or pear juices, \"sugar-free\" foods containing",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    , or high quantities of fructose)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restriction of fat from the diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. If the diet history suggests this possibility, we suggest an empiric trial of restricting juices and liberalizing dietary fat to 35 to 50 percent of total calories. Response to this dietary intervention supports the diagnosis of functional diarrhea and no further intervention is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the causes of chronic diarrhea in children\", section on 'Functional diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Selective testing according to stool type",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the diagnosis remains unclear after the above maneuvers, the next step is to narrow the diagnostic possibilities with clues from the history and by categorizing stool type.",
"   </p>",
"   <p>",
"    Although diarrhea is defined by excess water content, its clinical appearance typically falls into categories that inform further diagnostic testing (",
"    <a class=\"graphic graphic_table graphicRef53143 \" href=\"mobipreview.htm?30/52/31564\">",
"     table 4",
"    </a>",
"    ). Thus, a first step in the evaluation of chronic diarrhea is to determine whether the stool is watery, fatty, or inflammatory. In some cases, the stool will have a mixed appearance, requiring an evaluation that spans more than one category. As an example, diarrheal diseases of infectious origin commonly have watery and inflammatory components. Gross inspection of stool may be helpful, but laboratory testing usually will be necessary to categorize the stool accurately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Watery (osmotic versus secretory)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The water content of chronic diarrhea can be caused by secretory or osmotic processes, or a combination of the two. Distinguishing between these processes by measurement of fecal electrolytes, pH, reducing substances, and calculation of the osmotic gap helps to distinguish between these mechanisms and to categorize the cause of the diarrhea. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Stool pH, electrolytes, and reducing substances'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secretory &ndash; Secretory diarrhea usually is associated with large volumes of watery stools and persists during fasting. Consequently, it is helpful to assess the effects of fasting on stool output [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/1\">",
"       1",
"      </a>",
"      ]. Pure secretory diarrheas are uncommon, but may occur in the setting of some congenital diarrheas, certain enteric infections, and some neuroendocrine tumors (",
"      <a class=\"graphic graphic_algorithm graphicRef57351 \" href=\"mobipreview.htm?24/54/25440\">",
"       algorithm 2D",
"      </a>",
"      ). The latter typically cause acute diarrhea, but may become persistent if mucosal injury causes a post-infectious lactose intolerance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=see_link\">",
"       \"Evaluation of diarrhea in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of the causes of chronic diarrhea in children\", section on 'Congenital secretory and osmotic diarrheas'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link&amp;anchor=H33#H33\">",
"       \"Overview of the causes of chronic diarrhea in children\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osmotic &ndash; Osmotic diarrheas typically are less voluminous than secretory diarrheas (eg, &lt;200",
"      <span class=\"nowrap\">",
"       mL/day),",
"      </span>",
"      and improve or resolve during fasting. The presence of reducing substances or low fecal pH (ie, pH &lt;6) suggest carbohydrate malabsorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Osmotic diarrheas are characterized by relatively low sodium concentration (&lt;70",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    pH &lt;5.5, and a high osmotic gap (&gt;125",
"    <span class=\"nowrap\">",
"     mOsm/kg).",
"    </span>",
"    Diarrheas with mixed mechanisms often have intermediate osmotic gaps: between 50 and 125",
"    <span class=\"nowrap\">",
"     mOsm/kg",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef51596 \" href=\"mobipreview.htm?15/36/15947\">",
"     table 3",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/42/9890?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inflammatory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of gross or occult blood, fecal leukocytes, or elevation in fecal calprotectin (a protein found in leukocytes) indicates an inflammatory diarrhea. However, if the diarrhea has caused skin breakdown (eg, infants with marked diaper rash) or anal fissures, then a positive test for occult blood may not reflect an inflammatory diarrhea.",
"   </p>",
"   <p>",
"    If the stools contain substantial amounts of gross blood, the differential diagnosis includes noninflammatory sources of blood in the GI tract (eg, Meckel's diverticulum), as well as enteric pathogens (eg, C. difficile) and chronic inflammatory diseases (eg, dietary protein intolerance and inflammatory bowel disease). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29513?source=see_link\">",
"     \"Diagnostic approach to lower gastrointestinal bleeding in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fatty",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests can be used to detect fat malabsorption (steatorrhea). Quantitative and qualitative fecal fat tests are most accurate in patients with severe fat malabsorption caused by pancreatic insufficiency or bile acid secretory defects. Tests of fecal fat have low sensitivity and specificity for patients with other diarrheal diseases. Thus, these tests may be used as diagnostic clues to determine the order of an evaluation, but are not sufficient to definitively narrow the diagnostic possibilities. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Stool fat'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Specific testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial categorization of the diarrhea, the differential diagnosis becomes more manageable, and a more focused series of investigations can be pursued (",
"    <a class=\"graphic graphic_table graphicRef53143 \" href=\"mobipreview.htm?30/52/31564\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/6\">",
"     6",
"    </a>",
"    ]. Infectious and structural diseases that are consistent with the patient's history should be excluded first. Consecutively, specific tests guided by the initial categorization should be performed, followed by endoscopy and genetic testing if necessary to confirm the diagnosis and aid management (",
"    <a class=\"graphic graphic_algorithm graphicRef64254 graphicRef67133 graphicRef56277 graphicRef57351 \" href=\"mobipreview.htm?37/37/38488\">",
"     algorithm 2A-D",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Other tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic diarrhea associated with impaired nutritional status always should be considered a serious disease in infants, and therapy should be promptly started [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/9\">",
"     9",
"    </a>",
"    ]. Sufficient calories should be provided to allow for catch-up weight gain. When oral intake is inadequate or malabsorption precludes adequate intake, continuous enteral feedings or parenteral nutrition may be necessary. Parenteral nutrition should be undertaken as soon as other, less invasive nutritional approaches have been shown to be unsuccessful.",
"   </p>",
"   <p>",
"    Micronutrient and vitamin supplementation are part of nutritional rehabilitation, especially in malnourished children from developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Children with chronic diarrhea and malnutrition are often deficient in vitamin A, zinc,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    , copper, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/13\">",
"     13",
"    </a>",
"    ]. Deficiencies in these micronutrients can impair the function of the immune system and have a direct effect on the structure and function of mucosa. Zinc deficiency is a particular risk because of losses through the injured lining of the gastrointestinal tract during episodes of diarrhea, and empiric replacement of zinc is recommended for children with diarrhea and malnutrition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, treatment for chronic diarrhea is directed at the specific cause, once it is established. ((See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link\">",
"     \"Overview of the causes of chronic diarrhea in children\"",
"    </a>",
"    .) and related topic reviews). However, a few general approaches are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many diarrheal diseases are associated with alterations in the intestinal microbiota. An attempt at modifying this altered bacterial population may be worth considering, even when an infectious cause is suspected but not proven. Two distinct strategies are available: the administration of probiotic bacteria and the administration of antibiotics. Randomized studies and meta-analyses have demonstrated modest efficacy of probiotic administration both in the prevention and treatment of several types of acute and protracted diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .) The utility of treatment with antibiotics is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antidiarrheal drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/31/8692?source=see_link\">",
"     Loperamide",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     diphenoxylate/",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"      atropine",
"     </a>",
"    </span>",
"    may improve symptoms in children with severe and protracted diarrhea, but these agents have important side effects, including sedation and risk for toxic megacolon. For some infectious diarrheas they may prolong excretion of the organism or promote the development of hemolytic-uremic syndrome in patients infected with enterohemorrhagic E. coli. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=see_link\">",
"     \"Treatment and prevention of Shigella infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend the use of these or other antimotility drugs for children with chronic diarrhea, except in unusual circumstances to facilitate fluid management, when the cause of the diarrhea has been established (eg, irritable bowel syndrome), and the medication is administered under careful supervision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Somatostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment may be directed at modifying specific pathophysiologic processes. In severe secretory diarrheas for instance (such as in neuroendocrine tumors, microvillous inclusion disease, and enterotoxin-induced severe diarrhea), a trial with somatostatin or its analogue,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37991?source=see_link\">",
"     octreotide",
"    </a>",
"    , may be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/15\">",
"     15",
"    </a>",
"    ]. Octreotide has been used in diarrhea caused by neoplastic diseases and in intestinal infections. It also has been shown to be effective in reducing fecal output in HIV infected children with severe cryptosporidiosis. In vitro tests have shown that octreotide has a specific antagonist effect against the enterotoxic activity associated with Cryptosporidium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35511/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wide variety of problems can cause chronic diarrhea in infants and children, including functional and infectious causes as well as heritable disorders of immune regulation, macronutrient digestion, mucosal barrier function, and transport (",
"      <a class=\"graphic graphic_table graphicRef56837 \" href=\"mobipreview.htm?25/32/26125\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link\">",
"       \"Overview of the causes of chronic diarrhea in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To establish a diagnosis within this diverse set of disorders, an algorithmic approach is helpful (",
"      <a class=\"graphic graphic_algorithm graphicRef60860 \" href=\"mobipreview.htm?22/10/22692\">",
"       algorithm 1",
"      </a>",
"      ). The first step is a detailed history, which may provide clues to the diagnosis or diagnostic category (",
"      <a class=\"graphic graphic_table graphicRef81662 \" href=\"mobipreview.htm?12/27/12733\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest serologic testing for celiac disease for all children with chronic diarrhea, provided that their diet contains gluten. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Exclude celiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional diarrhea accounts for a high proportion of chronic diarrheas in young children. For children with characteristics typical of functional diarrhea, we suggest a diagnostic trial of restricting juices and liberalizing dietary fat. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Consider functional diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis is not clear after the above steps, categorizing the diarrhea by stool type will narrow the diagnostic possibilities and inform the order of further testing (",
"      <a class=\"graphic graphic_table graphicRef53143 \" href=\"mobipreview.htm?30/52/31564\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Selective testing according to stool type'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of the cause of the diarrhea, evaluation for and treatment of malnutrition is an important step in recovery. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Malnutrition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43609?source=see_link\">",
"       \"Persistent diarrhea in children in developing countries\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest NOT treating children with chronic diarrhea with antidiarrheal drugs such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/31/8692?source=see_link\">",
"       loperamide",
"      </a>",
"      and",
"      <span class=\"nowrap\">",
"       diphenoxylate/",
"       <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"        atropine",
"       </a>",
"       &nbsp;(",
"       <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"        Grade 2B",
"       </a>",
"       ).",
"      </span>",
"      In unusual circumstances in which the cause of the diarrhea has been established, these drugs may be used cautiously to overcome problems with fluid management. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Antidiarrheal drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/1\">",
"      Binder HJ. Causes of chronic diarrhea. N Engl J Med 2006; 355:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/2\">",
"      Bhutta ZA, Ghishan F, Lindley K, et al. Persistent and chronic diarrhea and malabsorption: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 Suppl 2:S711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/3\">",
"      Gibbons T, Fuchs GJ. Chronic enteropathy: clinical aspects. Nestle Nutr Workshop Ser Pediatr Program 2007; 59:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/4\">",
"      Bhandari N, Bhan MK, Sazawal S, et al. Association of antecedent malnutrition with persistent diarrhoea: a case-control study. BMJ 1989; 298:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/5\">",
"      Kleinman RE. Chronic nonspecific diarrhea of childhood. Nestle Nutr Workshop Ser Pediatr Program 2005; 56:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/6\">",
"      Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/7\">",
"      Hyman PE, Milla PJ, Benninga MA, et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 2006; 130:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/8\">",
"      Cohen SA, Hendricks KM, Mathis RK, et al. Chronic nonspecific diarrhea: dietary relationships. Pediatrics 1979; 64:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/9\">",
"      Evaluation of an algorithm for the treatment of persistent diarrhoea: a multicentre study. International Working Group on Persistent Diarrhoea. Bull World Health Organ 1996; 74:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/10\">",
"      Bhan MK, Bhandari N. The role of zinc and vitamin A in persistent diarrhea among infants and young children. J Pediatr Gastroenterol Nutr 1998; 26:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/11\">",
"      Rahman MM, Vermund SH, Wahed MA, et al. Simultaneous zinc and vitamin A supplementation in Bangladeshi children: randomised double blind controlled trial. BMJ 2001; 323:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/12\">",
"      Ochoa TJ, Salazar-Lindo E, Cleary TG. Management of children with infection-associated persistent diarrhea. Semin Pediatr Infect Dis 2004; 15:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/13\">",
"      Bhan MK, Bhandari N, Bahl R. Management of the severely malnourished child: perspective from developing countries. BMJ 2003; 326:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/14\">",
"      Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012; 7:e34938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/15\">",
"      Bisset WM, Jenkins H, Booth I, et al. The effect of somatostatin on small intestinal transport in intractable diarrhoea of infancy. J Pediatr Gastroenterol Nutr 1993; 17:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35511/abstract/16\">",
"      Guarino A, Berni Canani R, Spagnuolo MI, et al. In vivo and in vitro efficacy of octreotide for treatment of enteric cryptosporidiosis. Dig Dis Sci 1998; 43:436.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5881 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35511=[""].join("\n");
var outline_f34_43_35511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Celiac serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stool pH, electrolytes, and reducing substances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Occult blood and leukocyte markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stool fat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exclude celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Consider functional diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Selective testing according to stool type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Watery (osmotic versus secretory)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inflammatory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fatty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Specific testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Probiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antidiarrheal drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Somatostatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5881|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/10/22692\" title=\"algorithm 1\">",
"      Categorize chronic diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?15/26/15776\" title=\"algorithm 2A\">",
"      Osmotic diarrhea child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/24/11648\" title=\"algorithm 2B\">",
"      Inflammatory diarrhea child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?14/0/14350\" title=\"algorithm 2C\">",
"      Fatty diarrhea child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/54/25440\" title=\"algorithm 2D\">",
"      Secretory diarrhea child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/32/26125\" title=\"table 1\">",
"      Causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/27/12733\" title=\"table 2\">",
"      Medical history in children with chronic diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/36/15947\" title=\"table 3\">",
"      Stool electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/52/31564\" title=\"table 4\">",
"      Chronic diarrhea stool type",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/42/9890?source=related_link\" title=\"calculator 1\">",
"      Calculator: Stool osmolal gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6246?source=related_link\">",
"      Factitious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34201?source=related_link\">",
"      Pancreatic exocrine function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43609?source=related_link\">",
"      Persistent diarrhea in children in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=related_link\">",
"      Treatment and prevention of Shigella infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_43_35512="Parabasal cells";
var content_f34_43_35512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parabasal cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (A) and high (B) power microscopy of vaginal discharge reveals parabasal cells and a marked increase in inflammatory cells (primarily polymorphonuclear leukocytes).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35512=[""].join("\n");
var outline_f34_43_35512=null;
var title_f34_43_35513="Aplastic anemia bone marrow";
var content_f34_43_35513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow biopsy in aplastic anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow biopsy in aplastic anemia. There are virtually no hematopoietic cells, and the marrow space consists of fat and stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal bone marrow biopsy at low power",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35513=[""].join("\n");
var outline_f34_43_35513=null;
var title_f34_43_35514="Hypercoagulable disorders associated with malignancy";
var content_f34_43_35514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypercoagulable disorders associated with malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35514/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35514/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35514/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/43/35514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/43/35514/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/43/35514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer are in a hypercoagulable state. The spectrum of hemostatic abnormalities ranges from abnormal coagulation tests in the absence of clinical manifestations to massive, fatal thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thrombotic episodes may precede the diagnosis of malignancy by months or years and can present in one of the following ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Migratory superficial thrombophlebitis (Trousseau's syndrome)",
"     </li>",
"     <li>",
"      Idiopathic deep venous thrombosis and other venous thrombosis",
"     </li>",
"     <li>",
"      Nonbacterial thrombotic endocarditis (marantic endocarditis)",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC)",
"     </li>",
"     <li>",
"      Thrombotic microangiopathy",
"     </li>",
"     <li>",
"      Arterial thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to hypercoagulability, tumors can also lead to venous thrombosis by external compression of vessels or by vascular invasion. As examples, renal cell carcinoma infiltrates the inferior vena cava in 5 to 9 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/4\">",
"     4",
"    </a>",
"    ], hepatocellular carcinoma can compress or invade the hepatic vein(s), and a large mediastinal tumor or bulky axillary lymphadenopathy can lead to upper extremity venous thrombosis.",
"   </p>",
"   <p>",
"    The clinical features of the hypercoagulable syndromes that can be associated with malignancy will be discussed here. The pathogenesis of these disorders as well as drug-induced thrombosis and vascular disease in patients with malignancy are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=see_link\">",
"       \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link\">",
"       \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link\">",
"       \"Catheter-induced upper extremity venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of VTE in patients with malignancy is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TROUSSEAU'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between venous thrombosis and malignancy was first suggested in 1865 by Trousseau. Of interest, Trousseau subsequently developed unexplained deep venous thrombosis, followed a year later by the development of gastric carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trousseau's syndrome (migratory superficial thrombophlebitis, phlegmasia alba dolens) is a rare variant of venous thrombosis characterized by a recurrent and migratory pattern and involvement of superficial veins, frequently in unusual sites such as the arm or chest. The patient with Trousseau's syndrome usually has an occult tumor which is not always detectable at the time of presentation. If a tumor is discovered, it is usually an adenocarcinoma. In one review of patients with Trousseau's syndrome, the following associated tumors were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pancreas &mdash; 24 percent",
"     </li>",
"     <li>",
"      Lung &mdash; 20 percent",
"     </li>",
"     <li>",
"      Prostate &mdash; 13 percent",
"     </li>",
"     <li>",
"      Stomach &mdash; 12 percent",
"     </li>",
"     <li>",
"      Acute leukemia &mdash; 9 percent",
"     </li>",
"     <li>",
"      Colon &mdash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This syndrome occurs in up to 10 percent of patients with pancreatic carcinoma. Treatment is difficult;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    can relieve some of the manifestations, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    appears to be without effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mucin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucins produced by adenocarcinomas may trigger this syndrome by reacting with leukocyte and platelet selectins, resulting in the production of platelet-rich microthrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. As an example, one study has shown that, while thrombotic risk was increased 20-fold in patients with lung cancer, the relative risk of venous thrombosis was significantly higher in those with mucin-expressing tumors (eg, adenocarcinomas) than in the those with squamous cell tumors (hazard ratio 3.1; 95% CI 1.4-6.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathology of lung malignancies\", section on 'Adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has the property of blocking selectin recognition of ligands, a property not shared by vitamin K antagonists. This may explain the superior efficacy of heparin in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/10\">",
"     10",
"    </a>",
"    ]. This phenomenon was illustrated in a murine model of Trousseau syndrome, in which microthrombi formed independent of fluid-phase coagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/11\">",
"     11",
"    </a>",
"    ]. Mucins triggered reciprocal activation of platelets and neutrophils, and heparin was able to block mucin binding to P- and L-selectin. Of interest, these thrombi did not depend on the generation of thrombin to form, and their formation was blocked by a non-anticoagulant activity of heparin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\", section on 'LMW heparin versus warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cancers associated with thromboembolic events are clinically evident and have been previously diagnosed at the time of the event. However, some patients with venous thromboembolism (VTE) have an occult malignancy that is not diagnosed until many months following the event. While the incidence of VTE is increased in most patients with cancer, and anticoagulation can decrease this risk, there is a lack of convincing data that shows a survival benefit from anticoagulation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Prolongation of survival'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5789100\">",
"    <span class=\"h2\">",
"     Incidence of VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Known malignancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594791\">",
"    <span class=\"h4\">",
"     Overall risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical thromboembolism occurs in as many as 11 percent of patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/6\">",
"     6",
"    </a>",
"    ] and is the second leading cause of death in patients with overt malignant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/13\">",
"     13",
"    </a>",
"    ]. Autopsy series have described even higher rates of thrombosis for certain tumor types. One study, for example, found evidence of thrombosis in 30 percent of patients who died of pancreatic cancer; the incidence was over 50 percent in those with tumors in the body or tail of the pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/14\">",
"     14",
"    </a>",
"    ]. Other tumor types commonly associated with thromboembolic complications are carcinomas of the gastrointestinal tract, ovary, prostate, and lung. By virtue of its prevalence, lung cancer accounts for the largest number of thromboembolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An estimate of the magnitude of this problem was obtained from a study of the records of more than eight million Medicare patients admitted to a hospital between 1988 and 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The percent of patients with a diagnosis of deep vein thrombosis (DVT)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary embolus (PE) at the initial hospitalization was higher for those with malignancy, compared with those with nonmalignant disease (0.60 versus 0.57 percent).",
"     </li>",
"     <li>",
"      The probability of readmission with",
"      <strong>",
"       recurrent",
"      </strong>",
"      <span class=\"nowrap\">",
"       DVT/PE",
"      </span>",
"      within 183 days of initial hospitalization for patients with or without malignancy was 22 and 6.5 percent, respectively.",
"     </li>",
"     <li>",
"      The probability of death within 183 days of initial hospitalization for",
"      <span class=\"nowrap\">",
"       DVT/PE",
"      </span>",
"      among those with or without malignancy was 94 versus 29 percent, respectively. The adverse influence of venous thromboembolism on prognosis in cancer patients (particularly those with pancreatic cancer) has been shown by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/17-20\">",
"       17-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Those malignancies causing the greatest",
"      <strong>",
"       absolute number",
"      </strong>",
"      of episodes of",
"      <span class=\"nowrap\">",
"       DVT/PE",
"      </span>",
"      during this time period were lung, colon, and prostate, while those cancers with the highest",
"      <strong>",
"       rates",
"      </strong>",
"      of",
"      <span class=\"nowrap\">",
"       DVT/PE",
"      </span>",
"      (number of episodes per 10,000 patients with a specific malignancy) were ovary, brain, pancreas, and lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to hypercoagulability, tumors can also lead to venous thrombosis by external compression of vessels or by vascular invasion. As examples, renal cell carcinoma infiltrates the inferior vena cava in 5 to 9 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/4\">",
"     4",
"    </a>",
"    ], hepatocellular carcinoma can compress or invade the hepatic vein(s), and a large mediastinal tumor or bulky axillary lymphadenopathy can lead to upper extremity venous thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5789868\">",
"    <span class=\"h4\">",
"     Tumor-specific factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for VTE in patients with known malignancy have been evaluated in a number of large population-based, case-control studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. A number of these are discussed below.",
"   </p>",
"   <p>",
"    In a Danish cohort study of 57,591 cancer patients and a comparison control of 287,476 general population subjects, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Throughout nine years of subject accrual and follow-up, the incidence rates of VTE were higher among the cancer patients (IR 8.0; 95% CI 7.6-8.5) than among the general population (IR 4.7; 95% CI 4.3-5.1), especially in the first year after cancer diagnosis (IR 15.0 versus 8.6).",
"     </li>",
"     <li>",
"      Incidence rates were highest in patients with cancer of the pancreas (IR 41), brain (18), liver (20), multiple myeloma (23), and among those with advanced-stage cancer (28).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were obtained from a California study that linked cases from its cancer registry to the subsequent diagnosis of VTE from a patient discharge data set. The following results were obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 235,149 cancer cases, 3775 (1.6 percent) were diagnosed with definite or probable VTE within two years; 12 percent occurred at the time of diagnosis, and the remainder subsequently. The incidence rate of VTE was higher during the first year of follow-up than the second year for virtually all types and stages of cancer.",
"     </li>",
"     <li>",
"      Metastatic disease at the time of diagnosis was the strongest predictor for the development of VTE. The diagnosis of VTE was a significant predictor for decreased survival during the first follow-up year for all cancer types (median overall relative risk 3.7).",
"     </li>",
"     <li>",
"      Expressed as events per 100 patient-years, the highest incidences of VTE occurred during the first year of follow-up among cases with metastatic-stage cancer of the pancreas (20), stomach (10.7), bladder (7.9), uterus (6.4), kidney (6.0), and lung (5.0).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third study evaluated the incidence and effect of VTE on survival in 68,142 patients with colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/23\">",
"     23",
"    </a>",
"    ]. The two-year cumulative incidence of VTE was 3.1 percent, with rates of 5.0, 1.4, and 0.6",
"    <span class=\"nowrap\">",
"     events/100",
"    </span>",
"    patient-years for months zero to 6, months 7 to 12, and during the second year following diagnosis, respectively. Other findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant predictors of VTE included metastatic stage disease and the presence of three or more comorbid conditions.",
"     </li>",
"     <li>",
"      In risk-adjusted models, VTE was a significant predictor of death within one year of cancer diagnosis among patients with local or regional-stage disease, but not among those with metastatic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Patient factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the presence of a malignancy is associated with an increased risk for VTE, and some malignancies and their associated operations are associated with a higher risk of VTE than others (eg, prostate, esophagus, uterus, liver, pancreas, lung, gastrointestinal tract, brain) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/26\">",
"     26",
"    </a>",
"    ], cancer patients often have multiple co-morbidities that contribute to an increased risk for VTE. In addition to the risks attendant to hospitalization, immobilization, and surgery, these include advanced age, widespread or metastatic disease, presence of circulating tumor cells, tumor grade, presence of a central venous catheter, active chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy, presence of inherited thrombophilia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytosis, as well as transfusion of red cells or platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/21,27-39\">",
"     21,27-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a retrospective review of 43,808 patients undergoing one of 11 cancer surgical operations (breast resection, hysterectomy, prostatectomy, colectomy, gastrectomy, lung resection, hepatectomy, pancreatectomy, cystectomy, esophagectomy, nephrectomy), the following factors were significant predictors for development of VTE on multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Acquired thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased age",
"     </li>",
"     <li>",
"      Recent steroid usage",
"     </li>",
"     <li>",
"      BMI &ge;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Postoperative complications (eg, wound infection, reintubation, cardiac arrest, sepsis)",
"     </li>",
"     <li>",
"      Longer hospitalization (&gt;1 week)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594814\">",
"    <span class=\"h4\">",
"     Therapy-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs employed in cancer therapy have been associated with venous and arterial thrombosis (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , l-asparaginase,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ). This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link&amp;anchor=H12#H12\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Venous thromboembolism prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5789505\">",
"    <span class=\"h4\">",
"     VTE risk assessment scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk assessment scores for predicting the risk of VTE have been developed in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/40-47\">",
"     40-47",
"    </a>",
"    ]. Among these, the Khorana score has been validated in large cohorts of patients with malignancy; it is also simple to calculate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Khorana score estimates risk of VTE by assigning points based on the site of primary malignancy, hematologic parameters, and body mass index (BMI) (",
"      <a class=\"graphic graphic_table graphicRef73002 \" href=\"mobipreview.htm?14/28/14797\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients were stratified according to the number of points into three risk groups to predict the development of VTE. The cumulative incidence of VTE at 2.5 months ranged from 0.3 percent to 6.7 percent in patients with the fewest and most risk factors, respectively.",
"      <br/>",
"      <br/>",
"      The Khorana score was also validated in an independent study of 1415 patients with advanced malignancy enrolled in phase I chemotherapy trials (",
"      <a class=\"graphic graphic_table graphicRef73002 \" href=\"mobipreview.htm?14/28/14797\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Khorana score was modified in an observational cohort study (the Vienna Cancer and Thrombosis Study) to include additional high risk tumor types (brain, myeloma, kidney) and two additional variables: soluble P-selectin and D-dimer levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/49\">",
"       49",
"      </a>",
"      ]. In a retrospective analysis of this cohort, the cumulative incidences of VTE at six months were 1 percent for the lowest risk group (0 points) and 35 percent for the highest risk group (&ge;5 points).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies of patients with cancer have demonstrated that the incidence of VTE was higher in patients with elevated D-dimer levels, as well as other coagulation parameters (eg, peak thrombin, prothrombin fragment 1+2, tissue factor, fibrinogen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/41,42,50\">",
"     41,42,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 497,180 Taiwanese patients with cancer, VTE risk was over 10-fold higher than the reported incidence in the general Taiwanese population (185 versus 15.9 cases per 100,000 person years, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/47\">",
"       47",
"      </a>",
"      ]. The following factors were associated with an increased risk of VTE: prior history of VTE; primary site myeloma, prostate cancer, lung cancer, gynecologic cancer, sarcoma, or metastasis of unknown origin, and female sex in a patient age 40 to 80 years. VTE risk was lower among patients &gt;80 years, those with head and neck, endocrine, esophageal or breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Occult malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of uncontrolled or retrospective studies of patients with venous thromboembolism have indicated a clinically significant incidence of malignancy, diagnosed within the first 6 to 12 months after presentation with thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/51-55\">",
"     51-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of these studies, investigators reviewed the outcome of 4399 patients who had venography for suspected venous thrombosis. The subsequent incidence of malignancy was higher in the 1383 patients with thrombosis than in the 2412 patients without thrombosis (11 versus 7.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/51\">",
"       51",
"      </a>",
"      ]. The cancers in the group with thrombosis were more likely to have occurred within six months of the study (44 versus 20 percent).",
"     </li>",
"     <li>",
"      In a study of all patients in Denmark from 1994 to 2009, the standardized incidence ratios for the development of cancer within one year of a diagnosis of superficial venous thrombosis, DVT of the legs, or PE were 2.46, 2.75, and 3.27, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/55\">",
"       55",
"      </a>",
"      ]. After one year, the SIRs declined to 1.05, 1.11, and 1.14, respectively. For all three cohorts, strong associations were found for cancers of the liver, lung, ovaries, pancreas, and non-Hodgkin lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malignancies developing within the first two years after a diagnosis of VTE are also associated with a significantly poorer prognosis. This was shown in a retrospective study comparing overall survival in 4322 patients diagnosed with a first malignancy occurring within five years after a diagnosis of VTE to a group of 299,714 patients with malignancy but without VTE. Hazard ratios for death were 2.48, 1.21, 1.26, and 1.07 for malignancies diagnosed within six months, &gt;6 to 12 months, &gt;1 to 2 years, and &gt;2 to 5 years after the diagnosis of VTE, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A less prominent association was noted in a Danish nationwide study of almost 27,000 patients with DVT or pulmonary embolism; the occurrence of cancer in this cohort was determined by linkage to the Danish Cancer Registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/52\">",
"     52",
"    </a>",
"    ]. The standardized incidence ratio for cancer was 1.3 compared with those without DVT or pulmonary embolism. The risk of cancer was substantially elevated only during the first six months of follow-up and declined rapidly thereafter to a constant level slightly above 1.0 one year after the thrombotic event.",
"   </p>",
"   <p>",
"    A study linking over 500,000 cases in the California Cancer Registry with a hospital discharge database for VTE found a SIR for unprovoked VTE of 1.3 (95% CI 1.2-1.5) within one year prior to the diagnosis of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/56\">",
"     56",
"    </a>",
"    ]. The incidence of preceding VTE was significantly increased over that expected only during the four-month period immediately preceding the date of cancer diagnosis; almost all of these were in patients with an ultimate diagnosis of metastatic disease. Seven cancer types were associated with a significantly increased SIR: acute myeloid leukemia, non-Hodgkin lymphoma, and renal cell, ovarian, pancreatic, stomach, and lung cancer.",
"   </p>",
"   <p>",
"    A meta-analysis of 40 reports published between 1982 and 2007 found a threefold excess risk of occult cancer in patients with VTE when compared with subjects without VTE (RR 3.2; 95% CI 2.4-4.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/57\">",
"     57",
"    </a>",
"    ]. Risks were highest for occult cancers developing in the ovary (RR 7.0), pancreas (6.1), and liver (5.6).",
"   </p>",
"   <p>",
"    Several prospective studies have provided further data on this association. In one report, 250 consecutive patients with symptomatic DVT were evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/58\">",
"     58",
"    </a>",
"    ]. A cause or risk factor for the thrombosis was identified in 105 patients. Malignancy was identified at the time of diagnosis of the thrombotic event in 5 of 153 patients (3.3 percent) with no other identifiable risk factor. During a two-year follow-up, there was an increased incidence of cancer in the patients with idiopathic thrombosis compared with the 105 patients with secondary thrombosis (8 versus 2 percent). The incidence of cancer was considerably higher (17 percent) among the 35 patients with recurrent idiopathic venous thrombosis.",
"   </p>",
"   <p>",
"    In another series of 400 patients with DVT, 70 (18 percent) already had been diagnosed with malignancy at the time of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/59\">",
"     59",
"    </a>",
"    ]. Of the remaining 326 patients, 10 new malignancies were diagnosed among 137 patients (7.3 percent) with idiopathic DVT, compared with only three malignancies in 189 patients (1.6 percent) with secondary DVT.",
"   </p>",
"   <p>",
"    Other studies have reported a higher incidence of occult malignancy (up to 25 percent) among patients with idiopathic DVT or pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. This may be explained in part by the use of a more aggressive diagnostic approach for cancer, which included measurement of serum carcinoembryonic antigen and prostate specific antigen, chest radiography, upper gastrointestinal endoscopy, abdominal ultrasound, and computed tomography scanning.",
"   </p>",
"   <p>",
"    Venous thromboembolism appears more likely to be the presenting sign of pancreatic and prostate cancer, whereas it more frequently occurs late in the course of patients with breast, lung, ovarian, uterine, or brain cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VTE at least one year after the diagnosis of a malignancy may be indicative of a second malignancy. In a case-control population-based cohort study of 6285 patients with cancer and an episode of VTE, the relative risk of developing a second malignancy was 1.0 if the thrombotic episode occurred within one year following the diagnosis of the first cancer, but rose to 1.4 (95% CI 1.2-1.7) if the episode of VTE occurred more than one year after the diagnosis of the initial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Use of cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased incidence of subsequent malignancy among patients presenting with idiopathic DVT or pulmonary embolism has raised the question of whether extensive screening for cancer would be beneficial. The recommendations are varied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. The use of extensive screening in two studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/60,62\">",
"     60,62",
"    </a>",
"    ], as discussed above, as well as in a 2008 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/70\">",
"     70",
"    </a>",
"    ], appears to increase the incidence of detected malignancies. However, the incidence of cancer was also increased in the patients with secondary DVT in these studies, so that the relative risk of diagnosing malignancy among patients with unexplained DVT and secondary thrombosis was comparable to other studies.",
"   </p>",
"   <p>",
"    Several investigators have attempted to define risk factors to identify the subset of patients likely to benefit from extensive screening for malignancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, cancer was diagnosed in 16 of 136 patients (12 percent) with idiopathic DVT during the index hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/71\">",
"       71",
"      </a>",
"      ]. All 16 had one or more abnormalities suggestive of possible malignancy on at least one of the four components of the initial investigation: history, physical examination, basic laboratory testing, or chest X-ray. During follow-up at a median of 34 months, cancer was diagnosed in 3 of 122 patients (2.5 percent), similar to the age- and sex-matched United States population.",
"     </li>",
"     <li>",
"      In a second series, 13 new malignancies were diagnosed among 326 patients with DVT during a six-month follow-up period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/59\">",
"       59",
"      </a>",
"      ]. Ten of the 13 had some type of clinical abnormality at presentation, and seven were diagnosed within the first 16 days based upon patient characteristics and clinical findings on initial routine examination and laboratory testing.",
"     </li>",
"     <li>",
"      In an analysis of patients with symptomatic acute VTE enrolled in the RIETE registry, those in whom cancer was diagnosed within the next three months (\"hidden cancer\"), when compared with those who were not so diagnosed during this period, had an increased incidence of recurrent VTE, major bleeding, and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/72\">",
"       72",
"      </a>",
"      ]. On multivariate analysis, risk factors for such \"hidden cancer\" were age 60 to 75 years, presence of anemia, presence of bilateral DVT, and idiopathic (rather than secondary) VTE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of prospective studies demonstrating either cost-effectiveness or improved survival with aggressive diagnostic testing for malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/70,73-76\">",
"     70,73-76",
"    </a>",
"    ], we believe that the evaluation of patients with idiopathic DVT should be limited to a careful history, a complete physical examination (including digital rectal examination and testing for fecal occult blood, pelvic examination in women), and routine laboratory testing (complete blood count, chemistry panel including electrolytes, calcium, creatinine, and liver function tests, urinalysis, chest radiograph, and, in men over the age of 50, prostate-specific antigen). Any abnormality observed on initial testing should then be investigated aggressively. A routine aggressive search for malignancy in all patients does not appear to be warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/52,69,74,76\">",
"     52,69,74,76",
"    </a>",
"    ], except in patients with recurrent idiopathic DVT who represent a high-risk group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/58,59,67,72\">",
"     58,59,67,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hepatic vein and portal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis of the hepatic vein (the Budd-Chiari syndrome) or portal vein may be associated with myeloproliferative neoplasms (eg, polycythemia vera), the clonal disorder paroxysmal nocturnal hemoglobinuria, as well as renal cell and adrenal carcinomas, hepatomas, and other gastrointestinal malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common clinical findings of hepatic vein thrombosis are abdominal pain, hepatomegaly, and ascites. Splenomegaly and esophagogastric varices are seen with portal vein thrombosis. Laboratory and in vitro studies (eg, presence of the JAK2 mutation, spontaneous erythroid colony growth in the absence of erythropoietin) suggest that an occult myeloproliferative disorder may be present in as many as 75 percent of patients with apparently idiopathic hepatic or portal vein thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention of VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Surgical patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative deep vein thrombosis is more frequent in patients with known malignant disease than in the general population, occurring in as many as 40 percent of patients in clinical trials employing bilateral venography of the lower extremities. As a result, these patients should be considered as being at high risk for development of postoperative VTE, with 33 to 53 percent of VTE episodes occurring after hospital discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/78-83\">",
"     78-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one prospective observational study of 44,656 patients undergoing surgery for one of nine different malignancies, significant risk factors for the development of postoperative VTE included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;65",
"     </li>",
"     <li>",
"      Presence of metastatic disease",
"     </li>",
"     <li>",
"      Ascites",
"     </li>",
"     <li>",
"      Presence of congestive failure",
"     </li>",
"     <li>",
"      Body mass index &ge;25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &gt;400,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Serum albumin &lt;3.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Operation duration &gt;2 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall VTE was significantly more likely after gastrointestinal, lung, prostate, and",
"    <span class=\"nowrap\">",
"     ovarian/uterine",
"    </span>",
"    operations. In those experiencing an episode of VTE, 30-day mortality increased more than sixfold over those not experiencing VTE (8.0 versus 1.2 percent, respectively). Details on the use and duration of prophylactic anticoagulation were not provided, but the involved hospitals had a high compliance rate (93 percent) for in-hospital prophylactic anticoagulation. A high percentage of the patients developed VTE post-discharge, suggesting that more prolonged prophylactic anticoagulation may be warranted following major cancer surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific recommendations for the prevention of VTE in cancer patients undergoing surgery, consistent with the 2007 guidelines from the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/85-87\">",
"     85-87",
"    </a>",
"    ], are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hospitalized medical patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acutely ill hospitalized medical patients who are confined to bed and have active malignancy are at high risk for development of VTE, both symptomatic as well as asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/82,88,89\">",
"     82,88,89",
"    </a>",
"    ]. The 2007 ASCO guidelines recommend that hospitalized patients with cancer should be considered for anticoagulation for prevention of VTE if there is no active bleeding and there are no other contraindications to anticoagulant use (eg, recent surgery, preexisting bleeding diathesis, platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL,",
"    </span>",
"    coagulopathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/81,85-87\">",
"     81,85-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for the prevention of VTE in hospitalized cancer patients, consistent with these ASCO guidelines, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H5137695#H5137695\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Patients with a central venous catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the presence of a central venous catheter is a risk factor for VTE in cancer patients, there is no evidence to support the routine use of VTE prophylaxis to prevent central venous catheter thrombosis. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link&amp;anchor=H32#H32\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Thrombosis prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ambulatory and postoperative cancer patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ambulatory cancer patient has an increased risk for the development of VTE. The development of VTE, even after complete surgical resection for a primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/90\">",
"     90",
"    </a>",
"    ], is a risk factor for reduced survival in these patients, and may also compromise the patient's ability to receive and respond to definitive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This is especially true for exocrine pancreatic cancer, with most modern studies reporting an incidence of thrombosis ranging from 5 to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was addressed in an analysis of data from the National Cancer Institute of Canada Clinical Trials Group PA3 randomized trial of chemotherapy in ambulatory patients with advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients with VTE either at the time of randomization or during the study had a significantly higher risk of disease progression, a lower chance of achieving a response to treatment, and shorter overall survival than patients without VTE.",
"   </p>",
"   <p>",
"    Similar conclusions were made in a report of a single institution study of 1915 patients with pancreatic carcinoma treated with chemotherapy, in whom 690 (36 percent) developed a thrombotic event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/92\">",
"     92",
"    </a>",
"    ]. The development of a thrombotic event, especially within 1.5 months of diagnosis, conferred a significantly worse prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Efficacy of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not advocate the use of prophylactic anticoagulation for ambulatory patients with cancer receiving or about to receive chemotherapy, as there is not enough evidence available at this time to support its use. The 2007 ASCO guidelines, the 2012 ACCP Clinical Practice Guidelines, a 2009 Consensus Statement of major guidelines panels, and the 2012 Clinical Practice Guidelines in Oncology from the NCCN do not recommend routine VTE prophylaxis in ambulatory patients with cancer, except for those with multiple myeloma receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus chemotherapy or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/36,81,85,87,93,94\">",
"     36,81,85,87,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 guidelines from the NCCN, however, suggest that VTE prophylaxis might be appropriate for those with a Khorana score &ge;3 (",
"    <a class=\"graphic graphic_table graphicRef73002 \" href=\"mobipreview.htm?14/28/14797\">",
"     table 1",
"    </a>",
"    ) who put a higher value on avoiding VTE than on the increased risk of bleeding associated with anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/36\">",
"     36",
"    </a>",
"    ]. Prophylactic anticoagulation might also be considered on an individualized basis in patients who develop cancer and have a prior history of unprovoked venous thromboembolism if they are not chronically anticoagulated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link&amp;anchor=H642162558#H642162558\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Incidence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of randomized studies comparing various LMW heparins to placebo in cancer patients receiving chemotherapy",
"    <strong>",
"     without",
"    </strong>",
"    VTE have been performed providing data on the risks (eg, bleeding) and benefits (eg, reduction in the incidence of VTE, prolongation of survival) of such anticoagulation. Results from a number of these studies are presented below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Prolongation of survival'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23123069\">",
"    <span class=\"h5\">",
"     The PROTECHT study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PROTECHT study randomized 1150 patients to the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    (3800 anti-Xa IU subcutaneously once daily; 769 patients) versus placebo (381 patients) and evaluated prevention of thromboembolic events. Patients had metastatic or locally advanced lung, breast, gastrointestinal, ovarian, or head and neck cancer, an ECOG performance status of &le;2, and were receiving active chemotherapy. Study treatment was given for the duration of chemotherapy, up to a maximum of four months. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/95\">",
"     95",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of symptomatic venous and arterial thromboembolic events, the primary study outcome, was significantly lower in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"       nadroparin",
"      </a>",
"      -treated patients when compared with those receiving placebo (2.0 versus 3.9 percent).",
"     </li>",
"     <li>",
"      The rates of minor bleeding (7.4 versus 7.9 percent, respectively) and major bleeding (0.7 versus zero percent, respectively) were similar in the LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and placebo-treated groups. The rates of other serious adverse events thought to be related to the investigational drug were also similar (1.2 versus 1.6 percent, respectively).",
"     </li>",
"     <li>",
"      Thromboembolic rates in the placebo-treated patients were highest in those with cancers of the lung (8.8 percent) and pancreas (5.9 percent), suggesting that future studies should concentrate on these high-risk groups. (See",
"      <a class=\"local\" href=\"#H5789505\">",
"       'VTE risk assessment scores'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23123076\">",
"    <span class=\"h5\">",
"     The CONKO 004 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, randomized study of the efficacy and safety of adding the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously once daily) to chemotherapy in 312 patients with advanced pancreatic cancer (the CONKO 004 trial) has been presented in abstract form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/96\">",
"     96",
"    </a>",
"    ]. Initial results include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On an intent-to-treat analysis, there was a 65 percent relative risk reduction of symptomatic VTE following the use of LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (14.5 percent for the observation group versus 5.0 percent for the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      -treated group).",
"     </li>",
"     <li>",
"      Major bleeding events were noted in 6.3 and 9.9 percent of those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      or observation, respectively.",
"     </li>",
"     <li>",
"      Preliminary data showed no differences in time to progression or overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23123083\">",
"    <span class=\"h5\">",
"     The FRAGEM study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FRAGEM study randomized 123 patients with advanced or metastatic pancreatic cancer treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    to receive or not receive full therapeutic doses of the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    once daily for four weeks followed by 150",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    once daily for a further eight weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of VTE during the initial treatment period (ie, &lt;100 days), the primary efficacy endpoint, was significantly reduced in those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      (23 percent in those treated with chemotherapy alone versus 3.4 percent in those also treated with dalteparin; RR 0.145; 95% CI 0.035-0.612).",
"     </li>",
"     <li>",
"      The incidence of all-type VTE during the entire follow-up period was also significantly reduced in those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      (28 percent in those treated with chemotherapy alone versus 12 percent in those also treated with dalteparin; RR 0.419; 95% CI 0.187-0.935).",
"     </li>",
"     <li>",
"      There were five lethal episodes of VTE during the first 100 days of observation, which were seen only in the chemotherapy alone group. This difference was not statistically significant (8.3 versus 0 percent; RR 0.092; 95% CI 0.005-1.635).",
"     </li>",
"     <li>",
"      There were no significant differences in the secondary endpoints of overall survival (9.7 versus 8.7 months), time to progression (5.3 versus 5.5 months), or incidence of severe hemorrhage (3.2 versus 3.4 percent) between the two treatment arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23123090\">",
"    <span class=\"h5\">",
"     The SAVE-ONCO trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;This trial evaluated the efficacy and safety of the ultra LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    semuloparin (20 mg once daily by subcutaneous injection) versus placebo for the prevention of VTE in patients with metastatic or locally advanced solid tumors who were beginning a course of chemotherapy. Findings during the 3.5-month treatment period included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VTE occurred significantly less often in those treated with semuloparin than in those treated with placebo (1.2 versus 3.4 percent, respectively; HR 0.36; 95% CI 0.21-0.60). Efficacy of semuloparin was similar among subgroups defined according to the origin and stage of cancer and the baseline risk of VTE.",
"     </li>",
"     <li>",
"      Seven risk factors for VTE were evaluated, including presence of a central venous line, obesity, age &gt;75, chronic respiratory failure, chronic heart failure, venous",
"      <span class=\"nowrap\">",
"       insufficiency/varicose",
"      </span>",
"      veins, and a history of prior VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/99\">",
"       99",
"      </a>",
"      ]. The incidence of VTE in those with none of these risk factors (placebo treated group only) was 2.5 percent, while it was 12.5 percent in those with three or more of these risk factors.",
"     </li>",
"     <li>",
"      The incidences of clinically relevant bleeding (2.8 versus 2.0 percent) and major bleeding (1.2 versus 1.0 percent) were similar in the two treatment arms.",
"     </li>",
"     <li>",
"      Overall survival, assessed either at one year following randomization or seven months after randomization of the last subject, was similar in the two treatment arms (43.4 versus 44.5 percent, respectively; HR 0.96; 95% CI 0.86-1.06). [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/40-49\">",
"       40-49",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13726522\">",
"    <span class=\"h4\">",
"     Use of statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have suggested that the use of statins decreases the risk of VTE in several groups of medical patients (eg, healthy adults, subjects with atherosclerosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H28#H28\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of statin use on the risk of VTE in cancer patients was explored in a retrospective, case control study in 740 consecutive patients with a diagnosis of solid organ tumor, who were followed for an average duration of 10.2 months (range: 2 to 41 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/100\">",
"     100",
"    </a>",
"    ]. Findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multivariate analysis indicated that statin use was associated with a significant reduction in the risk of VTE (OR 0.33; 95% CI 0.18-0.59).",
"     </li>",
"     <li>",
"      As expected, the same analysis confirmed the presence of known factors that increase the risk of VTE, such as immobilization (OR 2.88), presence of metastatic disease (OR 2.07), and current chemotherapy (OR 1.77).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prolongation of survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited information on the use of anticoagulation to prolong survival in cancer patients without VTE. Available results are mixed, as noted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 11 randomized controlled studies has concluded that anticoagulation significantly reduced one-year overall mortality in cancer patients WITHOUT VTE by 8 percent for LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and 3 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , while increasing the risk for bleeding complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/101\">",
"       101",
"      </a>",
"      ]. Available trials did not permit subgroup analyses of the influence of cancer type and stage.",
"     </li>",
"     <li>",
"      A 2007 Cochrane review of five randomized controlled trials concluded that therapy with unfractionated or LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was associated with a clinically significant survival benefit (hazard ratio 0.77; 95% CI 0.65-0.91) in cancer patients without another reason for anticoagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/102\">",
"       102",
"      </a>",
"      ]. In a subgroup analysis, patients with limited small cell lung cancer experienced a clear survival benefit (HR 0.56; 95% CI 0.38-0.83) which was not seen in patients with advanced cancer of any site. The analysis could not rule out an increased risk of bleeding with heparin in these patients (RR 1.8; 95% CI 0.73-4.4).",
"     </li>",
"     <li>",
"      Results from a multicenter randomized study have indicated that use of the LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"       nadroparin",
"      </a>",
"      did not significantly improve median overall survival in 244 patients with advanced cancer (prostate, pancreas, non-small cell lung cancer) when compared with the 259 not receiving this agent (13.1 versus 11.9 months, respectively; adjusted hazard ratio 0.94; 95% CI 0.75-1.18) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/103\">",
"       103",
"      </a>",
"      ]. In addition, no difference in time to progression was observed between the two study arms. Major bleeding events were comparable between the two groups (4.1 versus 3.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of consistent data indicating a survival benefit, we agree with the 2007 ASCO guidelines, the 2008 ACCP guidelines, and the 2011 ESMO guidelines, which recommended against the use of anticoagulants for the purpose of improving survival in cancer patients without VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/85,104,105\">",
"     85,104,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of VTE in patients with cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ARTERIAL THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial thrombosis is less common than venous thrombosis in cancer patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort study, the incidence of arterial and venous thromboembolism among 66,106 hospitalized adult neutropenic cancer patients was 1.5 and 5.4 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort study of 504,208 hospitalized cancer patients who did not receive blood transfusions and were admitted between 1995 and 2003 at 60 medical centers, the overall rates of arterial and venous thromboembolism were 3.0 and 3.7 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/30\">",
"       30",
"      </a>",
"      ]. These rates were as high as 5.2 and 7.2 percent, respectively in those who did receive blood transfusions during their hospitalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such episodes of arterial thromboembolism are most frequently due to nonbacterial thrombotic endocarditis (see below), but some cases of acute ischemic stroke in patients with malignancy may be due to paradoxical brain embolism arising from deep vein thrombosis and a right-to-left shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombosis of the arterioles of the central nervous system and extremities may be associated with the myeloproliferative disorders, particularly essential thrombocythemia and polycythemia vera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/108\">",
"     108",
"    </a>",
"    ]. Digital ischemia may be a paraneoplastic phenomenon in solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NONBACTERIAL THROMBOTIC ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term nonbacterial thrombotic endocarditis (NBTE, marantic endocarditis, Libman-Sacks endocarditis, verrucous endocarditis) refers to a spectrum of lesions on the heart valves (most often aortic and mitral), usually in patients with advanced malignancy. In autopsy series, cancer has been found in as many as 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/110\">",
"     110",
"    </a>",
"    ]. The majority of NBTE is seen in patients with adenocarcinomas (eg, of the pancreas, lung, colon, or prostate); the incidence among patients with lung cancer may be as high as 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link&amp;anchor=H13#H13\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\", section on 'Nonbacterial thrombotic endocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vegetations consist of degenerating platelets interwoven with strands of fibrin. The masses vary in size from microscopic to large and exuberant with a tendency to cause extensive infarction if embolization occurs.",
"   </p>",
"   <p>",
"    The initiating factor in the pathogenesis of NBTE is unknown. Endothelial damage caused by circulating cytokines, such as tumor necrosis factor or interleukin-1, might trigger platelet deposition, particularly in the presence of an activated coagulation system. Laboratory evidence for disseminated intravascular coagulation (DIC) is often present.",
"   </p>",
"   <p>",
"    The major clinical manifestations of NBTE result from systemic emboli rather than valvular dysfunction. The vegetations are easily dislodged since there is little inflammatory reaction at the site of attachment. Common sites of embolization include the spleen, kidney, and extremities, but the most significant morbidity arises from emboli to the central nervous system and coronary arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Focal or diffuse neurologic abnormalities may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of NBTE should be considered in all cancer patients who develop an acute stroke syndrome as well as in patients presenting with cerebral embolism of unknown etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/113,115\">",
"     113,115",
"    </a>",
"    ]. The diagnosis of NBTE can be difficult to establish antemortem. Fewer than 50 percent of patients have audible cardiac murmurs, and small lesions (less than 3 mm) may not be identified by echocardiography.",
"   </p>",
"   <p>",
"    The preferred diagnostic test is transesophageal echocardiography (TEE), which is more sensitive than transthoracic echocardiography for the detection of vegetations. The potential value of TEE in this setting was illustrated in a series of 51 consecutive cancer patients with cerebrovascular events who were referred for TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/115\">",
"     115",
"    </a>",
"    ]. Almost one-half of patients had a definite cardiac source of embolism. Nonbacterial vegetations were detected in nine (18 percent); transthoracic echocardiography was performed in seven of these patients and was negative in four. Other sources of embolism included left atrial thrombus, complex aortic atheroma, and a patent foramen ovale or atrial septal defect in the presence of venous thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link&amp;anchor=H13#H13\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\", section on 'Nonbacterial thrombotic endocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use anticoagulation for patients with NBTE and systemic or pulmonary emboli, if there is no contraindication to anticoagulation. These patients should receive full-dose intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous low molecular weight (LMW) heparin, rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . This is in agreement with the American College of Chest Physicians (ACCP) guidelines on antithrombotic therapy published in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also use anticoagulation with full dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous LMW heparin in patients with disseminated cancer who are found to have aseptic vegetations.",
"   </p>",
"   <p>",
"    Anticoagulation should be continued indefinitely, since recurrent thromboembolism has occurred in patients following its discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/117\">",
"     117",
"    </a>",
"    ]. Treatment of the underlying malignancy, often metastatic at the time of diagnosis of NBTE, is generally unsatisfactory, but should be attempted in appropriate patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DISSEMINATED INTRAVASCULAR COAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC), resulting from generalized activation of the coagulation system, is the most common coagulopathy associated with malignancy. Malignancy is the third most frequent cause of DIC after infection and trauma, accounting for approximately 7 percent of clinically evident cases. DIC, which may be occult, has been reported in as many as 15 percent of patients with advanced disease and in most patients with acute promyelocytic leukemia (APL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Acute DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, overt DIC is rare in most malignancies, most often occurring with APL and adenocarcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/118\">",
"     118",
"    </a>",
"    ]. Two tumor cell procoagulants may be of primary importance in APL: tissue factor which forms a complex with factor VII to activate factors X and IX; and cancer procoagulant which activates factor X independent of factor VII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic DIC is manifested by bleeding due to utilization of clotting factors by the consumptive process. Affected patients may complain of minor bleeding from mucosal or cutaneous surfaces",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extensive life-threatening hemorrhage involving visceral sites. Among patients with APL, DIC is often present at the time of diagnosis or soon after the initiation of cytotoxic chemotherapy. It can cause pulmonary or cerebrovascular hemorrhage in up to 40 percent of patients and some studies report a 10 to 20 percent incidence of early hemorrhagic deaths. The induction of tumor cell differentiation with retinoic acid can lead to rapid improvement in the coagulopathy associated with acute promyelocytic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoma of the prostate also may be associated with hemorrhagic symptoms. However, the mechanism is different from DIC, being due to activation of fibrinolysis.",
"   </p>",
"   <p>",
"    Laboratory evaluation in DIC reveals a typical constellation of findings. These include prolongation of the prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time and reptilase time; thrombocytopenia; and reductions in plasma concentrations of fibrinogen and factors V and VIII. The most useful confirmatory test is the demonstration of increased levels of fibrin degradation products (FDPs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chronic DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic forms of DIC are more common in patients with cancer, particularly those with solid tumors. Most patients are asymptomatic while laboratory testing reveals low grade activation of coagulation with secondary fibrinolysis. The most common manifestations are modest reductions in plasma fibrinogen and the platelet count, elevated FDPs, and minimal changes in the PT or aPTT. A minority of affected patients have more obvious evidence of platelet, fibrinogen, and coagulation factor consumption. These patients often are hypercoagulable, and can present with deep vein thrombosis, Trousseau's syndrome, or NBTE.",
"   </p>",
"   <p>",
"    In one study of 1117 patients with solid tumors, DIC was present in 76 (6.8 percent); 50 patients presented with bleeding, while 31 presented with thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/121\">",
"     121",
"    </a>",
"    ]. On multivariate analysis, significant risk factors for development of DIC included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;60 years &mdash; odds ratio (OR): 5.1",
"     </li>",
"     <li>",
"      Male sex &mdash; OR: 4.3",
"     </li>",
"     <li>",
"      Breast cancer &mdash; OR: 4.0",
"     </li>",
"     <li>",
"      Tumor necrosis &mdash; OR: 3.4",
"     </li>",
"     <li>",
"      Advanced stage disease &mdash; OR: 2.6",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Median survival for patients with early stage tumors (stages I and II: 16 versus 44 months) as well as advanced stage tumors (stages III and IV: 9 versus 14 months) were significantly reduced in subjects with DIC, as compared with those without DIC, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     THROMBOTIC MICROANGIOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic microangiopathy (TMA) describes a syndrome characterized by a microangiopathic hemolytic anemia (MAHA) (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ), thrombocytopenia, microvascular thrombotic lesions, and the involvement of various specific organs. The two major TMA syndromes, which are thought to be pathogenetically similar, are thrombotic thrombocytopenic purpura (TTP) and the hemolytic-uremic syndrome (HUS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMA can also be seen as a complication of chemotherapy. This primarily occurs with one of four regimens:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ; and the use of radiation and high dose chemotherapy prior to hematopoietic cell transplantation (HCT). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H22#H22\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Chemotherapy agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TMA is thought to reflect direct platelet consumption, due to endothelial injury or primary platelet activation resulting in some cases from accumulation of unusually large von Willebrand factor multimers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This is different from the direct activation of the coagulation pathway in DIC. As a result, TMA is characterized by thrombocytopenia, increased turnover of platelets but not fibrin, and usually normal levels of the coagulation components and little or no prolongation of the prothrombin time or activated partial thromboplastin time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Disseminated malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of TMA with thrombocytopenia mimicking TTP have been reported in association with disseminated, occasionally occult, mucin-producing adenocarcinoma of the breast, gastrointestinal tract, pancreas, lung, or prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/123,125-129\">",
"     123,125-129",
"    </a>",
"    ]. Neurologic abnormalities, such as headache, confusion, or paresis, can be seen, but renal failure is uncommon in carcinoma-associated TMA. This complication can occur in as many as 6 percent of patients with metastatic carcinoma. There are two main differences between these patients and those with TTP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Levels of the von Willebrand factor cleaving protease (ADAMTS13) are normal or only mildly reduced and antibodies to ADAMTS13 are not present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/130-132\">",
"       130-132",
"      </a>",
"      ]. This is in contrast to the marked reduction of, and presence of autoantibodies to, ADAMTS13 seen in TTP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients respond poorly, if at all, to plasma exchange [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/126\">",
"       126",
"      </a>",
"      ], which is the standard of care in TTP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A search for systemic malignancy, including a bone marrow biopsy, is appropriate when patients with apparent TTP have atypical clinical features or fail to respond to plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Disseminated malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients presenting with this complication usually die within days to weeks of diagnosis unless the underlying malignancy can be controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/126-128,130,133-136\">",
"     126-128,130,133-136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ACTIVATION OF COAGULATION PRIOR TO THE CLINICAL DIAGNOSIS OF MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have documented an increased incidence of malignancy subsequent to the diagnosis of idiopathic VTE. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Venous thromboembolism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, increased thrombin generation may be associated with an increase in cancer mortality even in the absence of symptomatic thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/137,138\">",
"     137,138",
"    </a>",
"    ]. This issue was addressed in the Second Northwick Park Study, which evaluated 3053 middle-aged men clinically free of malignancy to determine whether activation of coagulation had an impact on subsequent mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/43/35514/abstract/137\">",
"     137",
"    </a>",
"    ]. Subjects with persistent activation of coagulation (ie, prothrombin fragment 1+2 and fibrinopeptide A concentrations in the upper quartile of the population distribution in two consecutive annual examinations) had an increased total mortality due to a higher mortality from all cancers, especially those of the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Two explanations for these observations are that the underlying malignancy produced a hypercoagulable state or that increased thrombin generation and activity might predispose to enhanced growth of malignant cells through promotion of angiogenesis and tumor cell proliferation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/62/994?source=see_link\">",
"       \"Patient information: Disseminated intravascular coagulation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783126885\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical thromboembolism occurs in as many as 11 percent of patients with cancer and is the second leading cause of death in patients with overt malignant disease. Thrombotic episodes may precede the diagnosis of malignancy by months or years and can present in one or more of the following ways:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Migratory superficial thrombophlebitis (Trousseau's syndrome) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Trousseau's syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Idiopathic deep venous thrombosis and other venous thrombosis (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Venous thromboembolism'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Nonbacterial thrombotic endocarditis (marantic endocarditis) (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Nonbacterial thrombotic endocarditis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC) (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Disseminated intravascular coagulation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Thrombotic microangiopathy (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Thrombotic microangiopathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Arterial thrombosis (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Arterial thrombosis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high incidence of hypercoagulable states in patients with cancer does",
"      <strong>",
"       NOT",
"      </strong>",
"      imply that all patients with a hypercoagulable state should be extensively screened for malignancy; however, it is important to pursue clinical symptoms and to perform age-appropriate cancer screening. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Occult malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk prediction scores for the development of thromboembolic disease for patients with malignancy have been developed (",
"      <a class=\"graphic graphic_table graphicRef73002 \" href=\"mobipreview.htm?14/28/14797\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5789505\">",
"       'VTE risk assessment scores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific recommendations for the prevention of VTE in medical and surgical patients with cancer are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in medical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pathogenesis of thromboembolic disease in patients with cancer and the treatment of cancer patients with established VTE are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=see_link\">",
"       \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=see_link\">",
"       \"Treatment of venous thromboembolism in patients with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/1\">",
"      Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 2003; 21:4194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/2\">",
"      Maraveyas A, Johnson M. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Br J Cancer 2009; 100:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/3\">",
"      Levine M. Treatment of thrombotic disorders in cancer patients. Haemostasis 1997; 27 Suppl 1:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/4\">",
"      Hedderich GS, O'Connor RJ, Reid EC, Mulder DS. Caval tumor thrombus complicating renal cell carcinoma: a surgical challenge. Surgery 1987; 102:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/5\">",
"      Siegelman ES, Needleman L. Venous thrombosis and cancer. N Engl J Med 1993; 328:885; author reply 886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/6\">",
"      Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/7\">",
"      Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med 1985; 79:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/8\">",
"      Woerner EM, Rowe RL. Trousseau's syndrome. Am Fam Physician 1988; 38:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/9\">",
"      Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003; 112:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/10\">",
"      Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/11\">",
"      Shao B, Wahrenbrock MG, Yao L, et al. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood 2011; 118:4015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/12\">",
"      Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 2:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/13\">",
"      Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/14\">",
"      Sproul EE. Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/15\">",
"      Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/16\">",
"      Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/17\">",
"      S&oslash;rensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/18\">",
"      Mandal&agrave; M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007; 18:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/19\">",
"      Mandal&agrave; M, Moro C, Labianca R, Ferretti G. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? J Clin Oncol 2007; 25:4320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/20\">",
"      Jones A, Stockton DL, Simpson AJ, Murchison JT. Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy. Br J Cancer 2009; 101:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/21\">",
"      Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/22\">",
"      Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/23\">",
"      Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/24\">",
"      Cronin-Fenton DP, S&oslash;ndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/25\">",
"      Anderson LA, Moore SC, Gridley G, et al. Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma 2011; 52:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/26\">",
"      De Martino RR, Goodney PP, Spangler EL, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg 2012; 55:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/27\">",
"      Mandal&agrave; M, Barni S, Floriani I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer 2009; 45:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/28\">",
"      Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/29\">",
"      Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 2008; 141:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/30\">",
"      Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/31\">",
"      Jacobson G, Lammli J, Zamba G, et al. Thromboembolic events in patients with cervical carcinoma: Incidence and effect on survival. Gynecol Oncol 2009; 113:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/32\">",
"      Pihusch R, Danzl G, Scholz M, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002; 94:3120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/33\">",
"      Mego M, De Giorgi U, Broglio K, et al. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 2009; 101:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/34\">",
"      Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/35\">",
"      Byrne M, Reynolds JV, O'Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer 2010; 102:73.",
"     </a>",
"    </li>",
"    <li>",
"     Streiff MB, Bockenstedt PL, Cataland SR, et al. NCCN Clinical Practice Guidelines in Oncology. Venous thromboembolic disease. Version 1.2012. www.nccn.org (Accessed on February 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/37\">",
"      Dipasco PJ, Misra S, Koniaris LG, Moffat FL Jr. Thrombophilic state in cancer, part I: biology, incidence, and risk factors. J Surg Oncol 2011; 104:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/38\">",
"      Chavez-MacGregor M, Zhao H, Kroll M, et al. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 2011; 22:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/39\">",
"      Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2012; 30:3870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/40\">",
"      Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/41\">",
"      Kirwan CC, McDowell G, McCollum CN, et al. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008; 99:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/42\">",
"      Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/43\">",
"      Mandal&agrave; M, Barni S, Prins M, et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010; 21:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/44\">",
"      Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/45\">",
"      Khorana AA. Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw 2011; 9:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/46\">",
"      Dutia M, White RH, Wun T. Risk assessment models for cancer-associated venous thromboembolism. Cancer 2012; 118:3468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/47\">",
"      Yu YB, Gau JP, Liu CY, et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost 2012; 108:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/48\">",
"      Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol 2012; 23:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/49\">",
"      Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/50\">",
"      Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/51\">",
"      Nordstr&ouml;m M, Lindblad B, Anderson H, et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 1994; 308:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/52\">",
"      S&oslash;rensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/53\">",
"      Gore JM, Appelbaum JS, Greene HL, et al. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 1982; 96:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/54\">",
"      Griffin, MR, Stanson, AS, Brown, ML, et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Intern Med 1987; 147:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/55\">",
"      S&oslash;rensen HT, Sv&aelig;rke C, Farkas DK, et al. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer 2012; 48:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/56\">",
"      White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/57\">",
"      Iodice S, Gandini S, L&ouml;hr M, et al. Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost 2008; 6:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/58\">",
"      Prandoni P, Lensing AW, B&uuml;ller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/59\">",
"      Hettiarachchi RJ, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998; 83:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/60\">",
"      Monreal M, Lafoz E, Casals A, et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 1991; 67:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/61\">",
"      Monreal M, Casals A, Boix J, et al. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest 1993; 103:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/62\">",
"      Bastounis EA, Karayiannakis AJ, Makri GG, et al. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med 1996; 239:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/63\">",
"      Bierry G, Holl N, Kellner F, et al. Venous thromboembolism and occult malignancy: simultaneous detection during pulmonary CT angiography with CT venography. AJR Am J Roentgenol 2008; 191:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/64\">",
"      Monreal M, Fernandez-Llamazares J, Perandreu J, et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997; 78:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/65\">",
"      Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005; 99:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/66\">",
"      S&oslash;rensen HT, Pedersen L, Mellemkjaer L, et al. The risk of a second cancer after hospitalisation for venous thromboembolism. Br J Cancer 2005; 93:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/67\">",
"      Prins MH, Hettiarachchi RJ, Lensing AW, Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Thromb Haemost 1997; 78:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/68\">",
"      Piccioli A, Prandoni P. Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost 2003; 1:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/69\">",
"      Lee AY. Screening for occult cancer in patients with idiopathic venous thromboembolism: no. J Thromb Haemost 2003; 1:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/70\">",
"      Carrier M, Le Gal G, Wells PS, et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 2008; 149:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/71\">",
"      Cornuz J, Pearson SD, Creager MA, et al. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/72\">",
"      Trujillo-Santos J, Prandoni P, Rivron-Guillot K, et al. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost 2008; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/73\">",
"      Monreal M, Lensing AW, Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004; 2:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/74\">",
"      Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/75\">",
"      Ornstein DL. A nickel's worth of cancer. Ann Intern Med 2008; 149:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/76\">",
"      Van Doormaal FF, Terpstra W, Van Der Griend R, et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 2011; 9:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/77\">",
"      Singh R, Sousou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost 2010; 8:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/78\">",
"      Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg. Is there a \"high risk\" group? Am J Surg 1970; 120:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/79\">",
"      Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/80\">",
"      Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. J Surg Oncol 2007; 96:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/81\">",
"      Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009; 115:5637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/82\">",
"      Kucher N, Spirk D, Baumgartner I, et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol 2010; 21:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/83\">",
"      Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 2011; 254:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/84\">",
"      Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/85\">",
"      Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/86\">",
"      Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 2009; 20:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/87\">",
"      Djulbegovic B. Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. J Support Oncol 2010; 8:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/88\">",
"      Browne AM, Cronin CG, English C, et al. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol 2010; 5:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/89\">",
"      Font C, Farr&uacute;s B, Vidal L, et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol 2011; 22:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/90\">",
"      Auer RA, Scheer AS, McSparron JI, et al. Postoperative venous thromboembolism predicts survival in cancer patients. Ann Surg 2012; 255:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/91\">",
"      Epstein AS, O'Reilly EM. Exocrine pancreas cancer and thromboembolic events: a systematic literature review. J Natl Compr Canc Netw 2012; 10:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/92\">",
"      Epstein AS, Soff GA, Capanu M, et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer 2012; 118:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/93\">",
"      Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27:4919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/94\">",
"      Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/95\">",
"      Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/96\">",
"      Riess H, Pelzer U, Deutschinoff G, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial (abstract). J Clin Oncol 2009; 27:798s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/97\">",
"      Maraveyas A, Waters J, Roy R, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Available at www.ncri.org.uk/ncriconference/2009abstracts/abstracts/LB112.htm. Accessed July 20, 2011. Abstract only.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/98\">",
"      Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/99\">",
"      Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/100\">",
"      Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/101\">",
"      Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/102\">",
"      Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007; :CD006652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/103\">",
"      van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011; 29:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/104\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/105\">",
"      Mandal&agrave; M, Falanga A, Roila F, ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 Suppl 6:vi85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/106\">",
"      Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/107\">",
"      Iguchi Y, Kimura K, Kobayashi K, et al. Ischaemic stroke with malignancy may often be caused by paradoxical embolism. J Neurol Neurosurg Psychiatry 2006; 77:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/108\">",
"      Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/109\">",
"      Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/110\">",
"      Deppisch LM, Fayemi AO. Non-bacterial thrombotic endocarditis: clinicopathologic correlations. Am Heart J 1976; 92:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/111\">",
"      Rosen P, Armstrong D. Nonbacterial thrombotic endocarditis in patients with malignant neoplastic diseases. Am J Med 1973; 54:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/112\">",
"      Gonz&aacute;lez Quintela A, Candela MJ, Vidal C, et al. Non-bacterial thrombotic endocarditis in cancer patients. Acta Cardiol 1991; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/113\">",
"      Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 1985; 64:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/114\">",
"      Johnson JA, Everett BM, Katz JT, Loscalzo J. Clinical problem-solving. Painful purple toes. N Engl J Med 2010; 362:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/115\">",
"      Dutta T, Karas MG, Segal AZ, Kizer JR. Yield of transesophageal echocardiography for nonbacterial thrombotic endocarditis and other cardiac sources of embolism in cancer patients with cerebral ischemia. Am J Cardiol 2006; 97:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/116\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/117\">",
"      Rogers LR, Cho ES, Kempin S, Posner JB. Cerebral infarction from non-bacterial thrombotic endocarditis. Clinical and pathological study including the effects of anticoagulation. Am J Med 1987; 83:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/118\">",
"      Lin PH, Lu YS, Lin CH, et al. Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation. Anticancer Res 2010; 30:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/119\">",
"      Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/120\">",
"      Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/121\">",
"      Sallah S, Wan JY, Nguyen NP, et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/122\">",
"      Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/123\">",
"      Laffay DL, Tubbs RR, Valenzuela R, et al. Chronic glomerular microangiopathy and metastatic carcinoma. Hum Pathol 1979; 10:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/124\">",
"      Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/125\">",
"      Chang JC, Naqvi T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist 2003; 8:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/126\">",
"      Francis KK, Kalyanam N, Terrell DR, et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist 2007; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/127\">",
"      Werner TL, Agarwal N, Carney HM, Rodgers GM. Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol 2007; 82:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/128\">",
"      George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) 2011; 25:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/129\">",
"      Robier C, Neubauer M, Beham-Schmid C, Sill H. Thrombotic microangiopathy and disseminated intravascular coagulation associated with carcinocythemia in a patient with breast cancer. J Clin Oncol 2011; 29:e825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/130\">",
"      Fontana S, Gerritsen HE, Kremer Hovinga J, et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 2001; 113:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/131\">",
"      Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999; 59:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/132\">",
"      Mannucci PM, Karimi M, Mosalaei A, et al. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica 2003; 88:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/133\">",
"      Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/134\">",
"      Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987; 24:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/135\">",
"      von Bubnoff N, Sandherr M, Schneller F, Peschel C. Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast. Am J Clin Oncol 2000; 23:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/136\">",
"      Lee JL, Lee JH, Kim MK, et al. A case of bone marrow necrosis with thrombotic thrombocytopenic purpura as a manifestation of occult colon cancer. Jpn J Clin Oncol 2004; 34:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/137\">",
"      Miller GJ, Bauer KA, Howarth DJ, et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004; 2:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/43/35514/abstract/138\">",
"      Karpatkin S. Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost 2004; 2:2103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1352 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35514=[""].join("\n");
var outline_f34_43_35514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H783126885\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TROUSSEAU'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mucin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5789100\">",
"      Incidence of VTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Known malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594791\">",
"      Overall risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5789868\">",
"      Tumor-specific factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patient factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594814\">",
"      Therapy-related factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5789505\">",
"      VTE risk assessment scores",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Occult malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use of cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hepatic vein and portal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention of VTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Surgical patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hospitalized medical patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Patients with a central venous catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ambulatory and postoperative cancer patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Efficacy of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H23123069\">",
"      - The PROTECHT study",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H23123076\">",
"      - The CONKO 004 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H23123083\">",
"      - The FRAGEM study",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H23123090\">",
"      - The SAVE-ONCO trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13726522\">",
"      Use of statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prolongation of survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of VTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ARTERIAL THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NONBACTERIAL THROMBOTIC ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DISSEMINATED INTRAVASCULAR COAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Acute DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chronic DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      THROMBOTIC MICROANGIOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Disseminated malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ACTIVATION OF COAGULATION PRIOR TO THE CLINICAL DIAGNOSIS OF MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H783126885\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1352\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1352|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1352|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/28/14797\" title=\"table 1\">",
"      Khorana score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/62/994?source=related_link\">",
"      Patient information: Disseminated intravascular coagulation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_43_35515="Albinism classification";
var content_f34_43_35515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular classification of albinism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of albinism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Responsible gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Oculocutaneous albinism (OCA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCA1",
"       </td>",
"       <td>",
"        Tyrosinase",
"       </td>",
"       <td>",
"        11q14-q21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCA2",
"       </td>",
"       <td>",
"        <em>",
"         OCA2",
"        </em>",
"        (",
"        <em>",
"         P",
"        </em>",
"        gene)",
"       </td>",
"       <td>",
"        15q11-q12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCA3",
"       </td>",
"       <td>",
"        Tyrosinase-related protein 1",
"       </td>",
"       <td>",
"        9p23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCA4",
"       </td>",
"       <td>",
"        <em>",
"         SLC45A2",
"        </em>",
"        *",
"       </td>",
"       <td>",
"        5p13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Ocular albinism (OA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OA1",
"       </td>",
"       <td>",
"        <em>",
"         GPR143",
"        </em>",
"       </td>",
"       <td>",
"        Xp22.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OA2",
"       </td>",
"       <td>",
"        <em>",
"         CACNA1F",
"        </em>",
"       </td>",
"       <td>",
"        Xp11.23",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Also known as",
"     <em>",
"      MATP",
"     </em>",
"     gene, encoding membrane-associated transporter protein.",
"    </div>",
"    <div class=\"reference\">",
"     Data modified and reproduced with permission from: Summers CG. Albinism: Classification, clinical characteristics, and recent findings. Optom Vis Sci 2009; 86:659. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35515=[""].join("\n");
var outline_f34_43_35515=null;
var title_f34_43_35516="Ingredient label terms for shellfish";
var content_f34_43_35516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to read an ingredient label for a shellfish-free diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Avoid foods that contain shellfish or any of these ingredients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barnacle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crawfish (crawdad, crayfish, ecrevisse)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Krill",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lobster (langouste, langoustine, Moreton bay bugs, scampi, tomalley)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prawns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shrimp (crevette, scampi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mollusks are not considered major allergens under food labeling laws and may not be fully disclosed on a product label.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Your doctor may advise you to avoid mollusks or these ingredients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abalone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clams (cherrystone, geoduck, littleneck, pismo, quahog)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cockle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cuttlefish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limpet (lapas, opihi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mussels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Octopus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oysters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periwinkle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scallops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sea cucumber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sea urchin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Snails (escargot)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squid (calamari)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whelk (Turban shell)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Shellfish are sometimes found in the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bouillabaisse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cuttlefish ink",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fish stock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucosamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seafood flavoring (eg, crab or clam extract)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surimi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Keep the following in mind:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Any food served in a seafood restaurant may contain shellfish protein due to cross-contact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For some individuals, a reaction may occur from inhaling cooking vapors or from handling fish or shellfish.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All FDA-regulated manufactured food products that contain a crustacean shellfish as an ingredient are required by US law to list the specific crustacean shellfish on the product label.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2010 The Food Allergy &amp; Anaphylaxis Network. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35516=[""].join("\n");
var outline_f34_43_35516=null;
var title_f34_43_35517="Renal survival in patients";
var content_f34_43_35517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Renal survival in patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 432px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal survival in patients with &le;1 g/d proteinuria at presentation differed significantly on the basis of increase in proteinuria from baseline. Group 1, 1 to 2 g/d increase; group 2, 2 to 3 g/d increase; group 3, &gt;3 g/d increase in proteinuria from baseline. p = 0.004 by trend test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18:3177. Copyright &copy; 2007 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35517=[""].join("\n");
var outline_f34_43_35517=null;
var title_f34_43_35518="Campylobacter jejuni colonies on CAMPY agar";
var content_f34_43_35518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Campylobacter jejuni colonies on CAMPY-agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isolation of Campylobacter jejuni from stool is best accomplished by use of CAMPY-agar, which contains several antibiotics to inhibit normal stool flora. Cultures are incubated at 42&ordm;C in a microaerophilic environment for 48 to 72 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_43_35518=[""].join("\n");
var outline_f34_43_35518=null;
var title_f34_43_35519="Contents: Adult orthopedics";
var content_f34_43_35519=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult orthopedics",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult orthopedics",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ankle and foot",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/49/32537\">",
"           Achilles tendinopathy and tendon rupture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/31/34296\">",
"           Ankle sprain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/58/1960\">",
"           Hallux valgus deformity (bunion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/40/44681\">",
"           Plantar fasciitis and other causes of heel pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/0/1030\">",
"           Posterior and medial ankle tendinopathies not involving the Achilles tendon",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Elbow",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/20/1354\">",
"           Epicondylitis (tennis and golf elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/40/14983\">",
"           Evaluation of elbow pain in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fractures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/36/29251\">",
"           Capitate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/43/12985\">",
"           Clavicle fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/13/42197\">",
"           Distal phalanx fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/13/21722\">",
"           Distal radius fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/6/26726\">",
"           Fibular fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/26/17828\">",
"           First (thumb) metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/58/17318\">",
"           General principles of acute fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/23/1400\">",
"           General principles of definitive fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/58/43941\">",
"           General principles of fracture management: Bone healing and fracture description",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/42/6823\">",
"           General principles of fracture management: Early and late complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/25/9620\">",
"           Hamate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/17/4376\">",
"           Initial evaluation and management of rib fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/61/24531\">",
"           Lunate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/9/22675\">",
"           Metacarpal base fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22707\">",
"           Metacarpal head fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/4/13382\">",
"           Metacarpal neck fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/5/20565\">",
"           Metacarpal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12614\">",
"           Metatarsal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/59/40885\">",
"           Middle phalanx fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/62/41960\">",
"           Midshaft femur fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/55/27510\">",
"           Midshaft humeral fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/33/36376\">",
"           Overview of ankle fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/49/4886\">",
"           Overview of carpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/6/2149\">",
"           Overview of metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/19/23866\">",
"           Overview of stress fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26358\">",
"           Overview of tibial fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/42/21157\">",
"           Patella fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/22/37218\">",
"           Pisiform fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/54/873\">",
"           Proximal fifth metatarsal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/54/29543\">",
"           Proximal humeral fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/36/20037\">",
"           Proximal phalanx fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/52/5957\">",
"           Proximal tibial fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/4/32838\">",
"           Radial head and neck fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/51/1848\">",
"           Scaphoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/52/28485\">",
"           Sesamoid fractures of the foot",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/50/43812\">",
"           Stress fractures of the humeral shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/61/33747\">",
"           Stress fractures of the metatarsal shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/4/19527\">",
"           Stress fractures of the tibia and fibula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/4/30790\">",
"           Tibial shaft fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44358\">",
"           Toe fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/3/36915\">",
"           Trapezium fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/39/33394\">",
"           Trapezoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/55/36723\">",
"           Triquetral fractures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General topics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/48/26375\">",
"           Burners (stingers): Acute brachial plexus injury in the athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/45/14041\">",
"           Bursitis: An overview of clinical manifestations, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/7/3193\">",
"           Diagnostic imaging of joint pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/37/32344\">",
"           Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/14/28904\">",
"           Evaluation of the adult with monoarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/15/34039\">",
"           Evaluation of the adult with polyarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/58/17318\">",
"           General principles of acute fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/23/1400\">",
"           General principles of definitive fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/58/43941\">",
"           General principles of fracture management: Bone healing and fracture description",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/10/2215\">",
"           Overview of overuse (chronic) tendinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/39/20089\">",
"           Overview of the management of overuse (chronic) tendinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/54/15208\">",
"           Splinting of musculoskeletal injuries",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hand",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/54/39783\">",
"           Dupuytren's contracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/17/25879\">",
"           Evaluation of the patient with hand pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/44/9928\">",
"           Evaluation of the patient with thumb pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38390\">",
"           Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/41/42645\">",
"           Finger and thumb anatomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/58/28581\">",
"           Flexor tendon injury of the distal interphalangeal joint (jersey finger)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/44/19141\">",
"           Trigger finger (stenosing flexor tenosynovitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/20/32068\">",
"           Ulnar collateral ligament injury (gamekeeper's or skier's thumb)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/40/27270\">",
"           de Quervain's tenosynovitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hip",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/39/1658\">",
"           Complications of total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/36/22088\">",
"           Evaluation of the adult with hip pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/9/39061\">",
"           Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/39/25210\">",
"           Radiologic evaluation of the painful hip in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10106\">",
"           Total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/33/18966\">",
"           Trochanteric bursitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Knee",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/24/32138\">",
"           Anterior cruciate ligament injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/32/16902\">",
"           Complications of total knee arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/29/6618\">",
"           Evaluation of the active adult patient with knee pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/48/28422\">",
"           Knee bursitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/11/3257\">",
"           Medial collateral ligament injury of the knee",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/15/16632\">",
"           Meniscal injury of the knee",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/61/43993\">",
"           Patellofemoral pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28565\">",
"           Synovectomy for inflammatory arthritis of the knee",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17514\">",
"           Total knee arthroplasty",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lower extremity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/35/14906\">",
"           Hamstring injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/4/34890\">",
"           Overview of running injuries of the lower extremity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neck",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/24/1418\">",
"           Evaluation of the patient with neck pain and cervical spine disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/36/23113\">",
"           Treatment of neck pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Shoulder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/25/44439\">",
"           Acromioclavicular joint disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/26/10663\">",
"           Acromioclavicular joint injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/24/25991\">",
"           Biceps tendinopathy and tendon rupture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/43/12985\">",
"           Clavicle fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/7/35961\">",
"           Evaluation of the patient with shoulder complaints",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/7/33912\">",
"           Frozen shoulder (adhesive capsulitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26630\">",
"           Glenohumeral osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/32/25095\">",
"           Management of rotator cuff tears",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/39/41592\">",
"           Multidirectional instability of the shoulder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/11/27834\">",
"           Physical examination of the shoulder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/46/6887\">",
"           Presentation and diagnosis of rotator cuff tears",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/36/36425\">",
"           Radiologic evaluation of the painful shoulder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/63/13305\">",
"           Rehabilitation principles and practice in shoulder impingement syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/50/21289\">",
"           Rotator cuff tendinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10378\">",
"           Shoulder dislocation and reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/33/32280\">",
"           Shoulder impingement syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sports medicine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/35/28215\">",
"           Chronic exertional compartment syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wrist",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/45/14039\">",
"           Anatomy and basic biomechanics of the wrist",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/15/42230\">",
"           Clinical manifestations and diagnosis of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/22/23911\">",
"           Etiology of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/21/12632\">",
"           Evaluation of the adult with acute wrist pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/52/20298\">",
"           Evaluation of the adult with subacute or chronic wrist pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/16/41223\">",
"           Ganglia and nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/3/32822\">",
"           Surgery for carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/62/44008\">",
"           Treatment of carpal tunnel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2775004CD4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f34_43_35519=[""].join("\n");
var outline_f34_43_35519=null;
